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Identification of small molecule inhibitors of the Mcm2-7 replicative helicase, 
and structural determination of mutants affecting the Mcm2/5 gate
 
Nicholas E. Simon, PhD 
University of Pittsburgh, 2014 
The replication of the eukaryotic genome is a highly regulated process requiring the coordinated 
efforts of several enzymes to ensure that multiple chromosomes are efficiently replicated once, 
and only once, per cell cycle. This coordination is largely achieved by loading and activating the 
eukaryotic replicative helicase, the molecular motor that separates duplex DNA, at different 
points in the cell cycle. Consistent with this central role in DNA replication’s regulation, the 
eukaryotic helicase, Mcm2-7, is unique among known helicases in that it is composed of six 
unique and essential subunits. Prior work has indicated that only a subset of these subunits are 
required for helicase activity, suggesting a regulatory role for the remainder. It has been posited 
that two of the subunits, Mcm2 and Mcm5, form an ATP dependent ‘gate’ involved in loading 
and/or activating the complex. The presence of this gate has been shown biochemically and 
structurally, but its physiological role remains speculatory. My dissertation research has focused 
on two areas. The first has been the identification and characterization of quinolone-based 
inhibitors, with the goal of finding compounds that selectively inhibit the subunits that make up 
the ‘gate.’ I have found that the fluoroquinolone ciprofloxacin and related compounds are 
selective for the Mcm2-7 helicase over other helicases and inhibit the complex in both in vitro 
DNA unwinding assays and in tissue culture. The second area of research has been determining  
iv 
the structure of regulatory mutants we predict have aberrant gate function with transmission 
electron microscopy and single particle image averaging. I have shown that the regulatory 
mutant mcm5bob1 biases the complex toward a closed state, potentially allowing for the 
premature loading of replication factors. I have also demonstrated that a mutation in the Walker 
B AAA+ ATPase active site motif in the active site between Mcm2 and Mcm6 changes the size 
of the Mcm2/5 gate, indicating a role for this active site in the regulation of Mcm2-7 topology. 
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1.0  INTRODUCTION 
“Decades later, DNA and genes captured the spotlight from enzymes; but in my theater, 
enzymes kept the leading role. DNA and RNA provide the script, but enzymes do the acting. 
For the cell, DNA is the construction manual, and RNA transcribes it into readable form, 
but the proteins, particularly the enzymes, carry out all the cellular functions and give the 
organism its shape” 
-Arthur Kornberg, For the Love of Enzymes: The Odyssey of a Biochemist 
1.1 EUKARYOTIC DNA REPLICATION 
The faithful replication of the eukaryotic genome is one of the most technically impressive 
feats in all of biology. In a highly regulated series of events, the largest macromolecules in 
nature are duplicated and segregated with incredible fidelity. Several enzymes contribute to 
active replication (Figure 1). Helicases unwind the double stranded DNA to form a single 
strand template. Single-stranded binding proteins bind and stabilize the release of single-
stranded DNA (ssDNA). Topoisomerases relieve torsional strain generated in the DNA 
substrate by the migrating replisome. Various polymerases are involved in the creation of 
RNA primers and the subsequent extension of nascent DNA along the leading and lagging 
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strands.  Care must be taken to not only faithfully duplicate the genome, but also ensure 
that each daughter cell receives a single copy of the complete genome. 
In eukaryotes, this is complicated by the presence of multiple, large chromosomes. 
Unlike in prokaryotes, multiple origins of replication are required in order to replicate all 
of the chromosomes in an efficient manner. This introduces an inherent problem: if the 
origins of replication load their replication machinery and begin replication (henceforth 
referred to as ‘licensing’ and ‘firing’ respectively) ad hoc, there exists a high likelihood 
that some origins may reinitiate and refire before a round of replication has finished. This 
has severe consequences for genome integrity, evidenced by the observation that 
unregulated origin firing has been shown to cause re-replication, leading to accumulation 
of ssDNA, head to head fork collisions, fork stalling or collapse, accumulation of aberrant 
DNA structures, and genome instability (reviewed in (Hook et al. 2007)). 
To avoid re-replication problems, eukaryotes employ a two-stage regulatory system 
for licensing and firing replication machinery. In the first step, components of the 
replisome are loaded onto chromatin, but remain catalytically inactive. The factors 
responsible for loading this machinery are then inactivated or removed from the nucleus, 
and only then is DNA replication initiated. This temporal separation of loading and 
activation events is what ensures that each round of licensing and firing happens once per 
cell cycle. 
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Figure 1: The Eukaryotic Replication Fork 
Overview of the proteins involved in eukaryotic replication. Shown are the polymerases (pol α, δ, 
and ε), the single stranded binding protein (RPA), the replicative topoisomerase Topo II, clamp loader (RFC), 
processivity factor (PCNA), the components of replicative helicase (Cdc45, GINS, and the Mcm2-7) 
A key player in this regulation is the eukaryotic replicative helicase, the molecular 
motor that unwinds double-stranded DNA (dsDNA) into a single-stranded DNA template 
for the rest of the DNA replication machinery. Although many factors are involved in 
origin licensing and firing, the replicative helicase is the only component found in both 
licensed origins and actively unwinding forks, making its activation the key regulatory 
event for the cell’s entry into S-phase (Bell and Dutta 2002). 
Consistent with this central importance in DNA replication, the eukaryotic 
replicative helicase, known to be the Mcm2-7 complex, is the most complicated helicase 
known. Like other replicative helicases it is a hexameric toroid, however unlike other 
helicases it is uniquely formed of 6 distinct and essential subunits, numbered 2-7, rather 
than six copies of a single protein like other well studied replicative helicases such as E1 
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and SV40 large T antigen. This unique subunit architecture has long been assumed to be a 
consequence of the multiple steps of the cell cycle it coordinates and the multitude of 
proteins it must interact with. Biochemical differences between subunits (Schwacha and 
Bell 2001; Bochman and Schwacha 2007; Bochman et al. 2008; Bochman and Schwacha 
2008) have been proposed to be indicative of Mcm2-7’s multiple roles in the cell cycle. 
1.1.1 Discovery and initial characterization of the Mcm Complex 
The name of the Mcm proteins derives from a screen designed to find mutants defective in 
plasmid (minichromosome) retention (Maine et al. 1984). In this screen, Maine et al. took 
advantage of the well-defined Autonomous Replicating Sequence in yeast, which are 
sequences that designate origins of replication, and constructed plasmids containing a 
centromere sequence and either a single or multiple ARSs. The resulting 40 mutants 
representing 16 complementation groups were accordingly named Minichromosome 
Maintenance (MCM) genes, and were divided into two classes: those in which plasmid 
retention could be rescued with multiple ARSs, posited to be involved in replication 
initiation, and those that were defective for plasmid segregation regardless of the ARS 
sequence, deemed general segregation mutants. 
Among the proposed initiation mutants where the genes MCM2, MCM3, and 
MCM5, all of which code for members of the Mcm helicase. Other notable, non-helicase 
mutants were in MCM1, which codes for a transcription factor that drives the expression of 
the Mcm complex (Jarvis et al. 1989; Passmore et al. 1989), and MCM10 (originally 
MCM4, see below), another DNA replication factor (Merchant et al. 1997). MCM4, MCM5 
and MCM7 were originally isolated as CDC54, CDC46 and CDC47 in an earlier screen for 
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cold-sensitive cell cycle division mutants (Moir et al. 1982). This screen is also notable for 
isolating the CMG complex member CDC45. The last member of the complex, MCM6, 
was not identified until ten years later when it was isolated as the missegration mutant mis5 
in a screen done in the fission yeast Schizosaccharomyces pombe (Takahashi et al. 1994). 
In 1996 it was established that the six proteins worked in concert, were homologous, and 
thus far found in all eukaryotes. It was proposed for clarity’s sake that the nomenclature be 
standardized and the genes were all assigned consecutive MCM designations, 2 through 7, 
and the original MCM4, MCM6, and MCM7 were renamed MCM10, MCM11, and MCM12 
(Chong et al. 1996). 
 
1.1.2 The different Mcm subunits have diverse functions 
Mcm2-7, like several other hexameric helicases, is a member of the ATPase associated 
with cellular activities superfamily (AAA+). This family of proteins has been extensively 
reviewed (Erzberger and Berger 2006) however, the salient features of the superfamily as 
they apply to the Mcms will be discussed here. Like other typical members of this 
superfamily, the ATPase active sites are formed in trans between neighboring subunits. 
Canonical Walker A, Walker B motifs (Walker et al. 1982)  and sensor I (Guenther et al. 
1997) motifs are contributed by one subunit, and the arginine finger (Wittinghofer et al. 
1997) and sensor II (Guenther et al. 1997) motifs are contributed by the neighboring 
subunit (Figure 2). 
This architecture necessitates oligomerization of subunits to form a functional 
active site. The eukaryotic Mcm complex also has the additional constraint of having 6 
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different subunits, resulting in six unique pairs forming six active sites, assuming only one 
oligomeric state exists in vivo. Consistent with this assumption, pairwise combinations of 
Mcm proteins able to dimerize provided a putative subunit order (Davey et al. 2003; 
Bochman et al. 2008), which was subsequently confirmed via electron microscopy of 
tagged subunits (Costa et al. 2011; Fernandez-Cid et al. 2013; Sun et al. 2013). Notably, 
hexamer-sized complexes containing only Mcm4, 6, and 7 have been shown by multiple 
groups to have in vitro helicase activity (Ishimi 1997; Lee and Hurwitz 2000; Kaplan et al. 
2003; Bochman and Schwacha 2007). More recently hexamers containing only Mcm4 and 
Mcm7 (Kanter et al. 2008) and, curiously, hexamers of Mcm6 alone from pea plants (Tran 
et al. 2010), have been shown to have in vitro helicase activity, indicating that other, 
presumed non-canonical, active site pairings can form functional ATPases, but to date it 
has not been shown if these have physiological relevance. 
The observation that only a subset of the Mcm proteins are necessary for DNA 
unwinding runs contrary to many hexameric helicase activity models (Patel and Picha 
2000). Quite the contrary, the presence of Mcm2, 3, and 5 actually prevents helicase 
activity of the Mcm2-7 hexamer except under specific assay conditions (Bochman and 
Schwacha 2008). This raises an obvious question: what do the remaining subunits do?  
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 Figure 2: Location and functions of active sites in the Mcm2-7 complex 
 
Schematic representation of the Mcm subunits as proposed by (Davey et al. 2003) and (Bochman et al. 2008), 
confirmed by (Costa et al. 2011) and (Speck et al. 2005), with proposed functions associated with the 2/5, 3/7 
(Bochman and Schwacha 2008), and 6/2 active sites (E. Tsai and S. Vijayraghavan, in preparation). Inset: 
Cartoon representation of the 3/7 AAA+ active site. Mcm7 provides canonical Walker A (A) and Walker B 
(B) motifs, while Mcm3 contributes the Arginine Finger (R) motif in trans. 
 
Walker A mutations in any of the subunits results in lethality in yeast (Bochman et 
al. 2008), indicating that each of these active sites performs an essential function not 
compensated for by the other five. Addressing this question has been the subject of a great 
deal of Mcm biochemistry that supports the hypothesis that these different subunits serve 
different functions. The strongest evidence of this is the fact that subcomplexes of Mcm467 
have in vitro helicase activity, but the addition of Mcm2, 3, and 5 abolish helicase activity 
unless the reaction is supplemented with large anions (Bochman and Schwacha 2008). 
Additionally, the Mcm4/7 and 7/3 active sites contribute to the majority of bulk ATP 
hydrolysis in solution (Schwacha and Bell 2001). These data suggested that active sites 
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formed by Mcm4, 6, and 7 are primarily responsible for DNA unwinding. Since the 
additional subunits make helicase activity conditionally dependent on reaction conditions, 
it was thought that they may be negatively regulating the activity of the complex.  
Biochemical comparison of the Mcm2-7 and Mcm467 complexes provided the first 
evidence that this might be the case, first showing that Mcm2-7 binding kinetics for 
ssDNA was slower than that of Mcm467, but were increased to equivalent rates after ATP 
preincubation (Bochman and Schwacha 2007). This was later demonstrated by the fact that 
Mcm2-7, unlike Mcm467, is capable of binding circular DNA substrates. These differences 
were reliant on the ATPase active site assumed to form between Mcm2 and Mcm5. 
Notably, unlike the other subunit pairs, these two subunits do not dimerize without 
crosslinking (Davey et al. 2003),  suggesting the existence of an ATP dependent gate 
between Mcm2 and Mcm5 (Bochman and Schwacha 2008), later confirmed by electron 
microscopy (Costa et al. 2011).  
Is this gate relevant physiologically? All published work regarding its existence to 
date has been done in biochemical or structural studies, and most mutants that cause 
aberrant gate states biochemically are lethal. However, one can speculate roles for such a 
discontinuity at various points in the cell cycle, such as loading of the complex onto DNA 
and during the transition from G1-phase to S-phase (Figure 3) 
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 Figure 3: Proposed conformational changes of Mcm2-7 during the cell cycle 
After loading, the Mcm2-7 complex transitions from dsDNA bound form to a ssDNA bound form. 
Reproduced from (Boos et al. 2012) with the permission of Elsevier  
 
1.1.2.1 Loading of the helicase at origins of replication 
Beginning in late mitosis, origins of replication are first bound by the six-protein Origin 
Recognition Complex in an ATP-dependent matter (Bell and Stillman 1992). The loading 
factors Cdt1 and Cdc6 then load Mcm2-7 at ORC-bound sites and collectively these 
components make up the licensed Pre-replication complex (Pre-RC). Since Mcm 
complexes are assembled as hexamers before entry into the nucleus (Nguyen et al. 2000), 
there must be some method for opening the toroid so it can be loaded onto DNA. One can 
speculate a role for the 2/5 gate during the loading phase, as the open state, in which the 
complex has no helicase activity (Bochman and Schwacha 2008), would be conducive to 
loading the complex onto DNA. In disagreement with this hypothesis is the recent OCCM 
structure (Sun et al. 2013), in which the Mcms, in complex with ORC and Cdt1, are bound 
around DNA but do not show a prominent 2/5 gate reported by other groups. One possible 
explanation for this discrepancy is in the purification of these complexes, as the OCCM 
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structure involves a high salt wash in which loosely bound proteins are washed off DNA, 
which may bias the system towards complexes that have securely closed around DNA. 
1.1.2.2 Initiation 
Unlike prokaryotes, eukaryotes possess numerous origins of replication, which necessitates 
a method for coordinating the start of DNA replication between these sites to prevent 
relicensing and refiring of Pre-RCs once DNA replication has commenced. This is 
achieved through an irreversible initiation step required to activate the helicase.  
The actual trigger for the start of initiation remains cryptic, but it is known that in S. 
cerevisiae one of the first events is the phosphorylation of Pre-RC components by the 
regulatory kinases Cyclin-Dependent Kinase (CDK) and DBF4-Dependent kinase 
(DDK)(Labib 2010). The essential substrates of CDK for initiation are Sld2 and Sld3, 
which when phosphorylated interact with Dbp11 (Zegerman and Diffley 2007). Dpb11 in 
turn recruits CDC45 and GINS to Mcm2-7 for assembly of the CMG complex (Takayama 
et al. 2003). At this time, extensive remodeling of the DNA and proteins at the origin 
occurs. The Mcm complex shifts from a dsDNA-bound state to a ssDNA-bound state, and 
the release of origin ssDNA displaces SLD3, allowing for GINS to take its place (Bruck et 
al. 2011; Bruck and Kaplan 2011b; Bruck and Kaplan 2011a). DDK phosphorylates 
multiple members of the Mcm complex, and can be bypassed entirely with a P83L 
mutation in Mcm5 (mcm5bob1)(Hardy et al. 1997). Notably, this mutation is predicted to 
cause a conformational change in the complex (Fletcher et al. 2003), and is a likely 
candidate for a mutation that disrupts normal Mcm gate function (discussed in detail 
below). 
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1.1.2.3 The S-phase checkpoint and termination. 
Unpublished data from our lab implicates the Mcm6/2 active site in the replication 
checkpoint (E Tsai, and S. Vijayraghavan, in preparation). Furthermore, it has been 
observed that CDC45 has ssDNA binding capabilities that are important for fork stalling 
during replication stress (Bruck and Kaplan 2013). Given that conformational changes 
involving the gate control Mcm2-7’s in vitro helicase activity, one can speculate that 
ATPase activity at the 6/2 active site and/or CDC45 dissociation open the complex to stall 
replication fork progression when the replisome encounters DNA damage. 
Finally, it’s conceivable that the 2/5 gate may play a role in termination. The details 
of termination in eukaryotes are poorly studied, but the gate could be necessary to remove 
the Mcms from chromatin at the end of S-phase. 
Numerous hypotheses can and have been made about the functional roles the gate 
may play in vivo. The following sections will discuss two promising tools for dissecting 
gate function and the role they’ve played thus far in understanding helicase function: small 
molecule helicase inhibitors and structures of different Mcm helicases. 
1.2 PROBING MOLECULAR FUNCTION OF HELICASES WITH SMALL 
MOLECULE INHIBITORS 
As discussed above, the heterohexameric nature of the Mcm2-7 complex makes it unique 
among replicative helicases in that the six members of the hexamer are different proteins. 
From an experimental standpoint, this allows for selective inactivation of a single subunit 
of the helicase. Indeed, this strategy has been use to great effect in biochemical studies of 
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the Mcm complex (Schwacha and Bell 2001; Bochman and Schwacha 2007; Bochman et 
al. 2008; Bochman and Schwacha 2008; Bochman and Schwacha 2010). 
While these studies have been illuminative in identifying subunits that primarily 
contribute to DNA unwinding, it is becoming clear that, unlike their prokaryotic 
counterparts, the Mcms do much more than unwind dsDNA, and are involved in the 
coordination of several regulatory events. These aspects are less amenable to biochemical 
examination, and ideally could be studied through genetic manipulations. However, like 
most replication proteins, all of the Mcm proteins are essential (Labib et al. 2000). 
Furthermore, most mutations made in the conserved AAA+ ATPase active sites are lethal 
(Bochman et al. 2008). 
Small molecule inhibitors provide a useful alternative to traditional genetic 
techniques. They offer the ability to inactivate a protein with precise timing without relying 
on mutants. The lack of genetic manipulations required simplifies assay design, is 
conducive to high throughput analysis, and allows for the stoppage of proteins in systems 
less amenable molecular cloning, such as Xenopus laevis extracts. Indeed, small molecules 
such as HU and Nocodozole have had long histories in the DNA replication field. Beyond 
the laboratory, inhibitors of DNA replication machinery have potential for therapeutic use, 
as cancer cells undergo rounds of DNA replication at a faster rate than normal cells. 
To date, bacterial and eukaryotic topoisomerases have both been used as clinical 
targets. Bacterial topoisomerase (DNA gyrase) inhibitors are the target of several classes of 
antibiotics, such as the quinolones (and associated derivatives) and aminocoumarins, both 
of which are widely used clinically. In humans, Topo I and Topo II are both validated 
cancer targets. Topo I inhibitors such as camptothecin are used clinically, and there are a 
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wide variety of Topo II inhibitors, including etopside, anthracyclines, and mitoxantrone 
used in the treatment of cancer (reviewed in (Pogorelcnik et al. 2013)). 
By comparison, helicases are a relatively underutilized therapeutic target, especially 
in light of their pervasiveness among biological processes. The most successful strategies 
for inhibiting helicases have been found in the search for antiviral compounds, specifically 
targeting the SF1 helicase UL5 from Herpesviridae family of viruses (Shadrick et al. 
2013). 
1.2.1 Identifying helicase inhibitors 
The primary difficulty in identifying new helicase inhibitors lies in the fact that DNA 
unwinding involves the interaction of the helicase, ATP, and double stranded DNA. The 
ternary nature of the reaction is highly susceptible to false positives, and is particularly 
vulnerable to compounds that non-specifically interact with DNA. A variety of 
experimental strategies have been developed to circumvent this problem, including creative 
substrate design, counterscreening, structure-based rational design, and alternative readouts 
to DNA unwinding.  
1.2.1.1 Bacterial Replicative Helicase inhibitors 
The prokaryotic helicase DnaB has been the target of several inhibitor studies, however 
most of these studies assayed compounds against the DnaB helicase from benign 
laboratory E. coli, and resulted in the identification of few compounds and/or compounds 
of low potency (Earnshaw et al. 1999; Earnshaw and Pope 2001; Zhang et al. 2002; Griep 
et al. 2007). However, these initial studies have led to the development of high throughput 
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assays, which has resulted in the identification of compounds with much greater 
therapeutic promise. Mckay et al. utilized the assay developed by Zhang et al. (Zhang et al. 
2002) to screen over 230,000 compounds against the DnaB from Pseudomonas 
aeruginosa, identifying triaminotriazines with low micromolar inhibition (McKay et al. 
2006).  
More recently, Aiello et al. performed a fluorescent helicase assay based screen 
against the DnaB helicases from Bacillus antracis and Staphylococcus aureus, screening 
over 186,000 compounds and identifying 160 which inhibited helicase activity. Eighteen of 
these remained after counterscreening eliminated false positives (Aiello et al. 2009). Of 
these, the coumarin-based compounds exhibited the highest potency and selectivity against 
bacterial cells with low general cytotoxicity. The same FRET-based method was later used 
in the identification of benzobisthiazole derivatives with nanomolar potency, shown to be 
acting competitively with the DNA substrate (Li et al. 2013). 
1.2.1.2 Viral Helicase inhibitors 
The helicase/primase complex UL5 from the Herpesviridae (HSV) is the most successful 
example of a helicase drug target to date, with multiple compounds that inhibit the 
complex used as antivirals clinically. Many of the high throughput techniques used to 
identify helicase inhibitors were first developed in HSV (reviewed in (Shadrick et al. 
2013)).  
The other class of viral helicases widely studied come from polyomavirsuses and 
papillomavirsuses. The viral replication factor large T-antigen (TAg) has recently been the 
focus of multiple high throughput screens, with the hope of developing treatments for 
polyoma virus infection in immunocompromised individuals. Given that TAg from SV40 
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is a well-studied AAA+ hexameric replicative helicase, strategies and compounds from 
these studies may be applicable to finding inhibitors of the Mcm complex. SV40 inhibitor 
studies have largely focused on inhibiting ATPase activity (Wright et al. 2009; Seguin et 
al. 2012) 
Why has there been such greater success in developing treatments targeting viral 
helicases as opposed to bacterial helicases? It has been posited that one reason may be viral 
helicases, in addition to their DNA unwinding function, coordinate other regulatory events 
as well (Shadrick et al. 2013). Indeed, large T antigen exemplifies this particularly well, as 
the various domains of the complex have been tied to a large number of different cellular 
processes. This multifunctional nature of viral helicases makes them indispensable to a 
variety of viral functions, rather than just bulk replication. This not only increases potency 
of small molecule inhibitors, as more cellular systems are impacted, but also lowers the 
likelihood of second site suppressor mutations occurring, since multiple processes are 
compromised.  
This coordination of disparate regulatory events is also seen in the Mcm2-7 
complex, discussed above, which may make it an attractive target for inhibitor studies. 
 
1.2.2 Inhibitors of the Eukaryotic Replicative helicase 
In contrast to their prokaryotic and viral counterparts, no high throughput screens 
have been performed on Mcm2-7. One reason for this is largely practical: it is difficult to 
purify Mcm2-7 and the CMG complex in amounts large enough to perform these screens, 
and in vitro helicase activity has not been demonstrable for the whole complex until 
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recently. However, there have been individual compounds identified that disrupt the 
complex’s activity and expression. The compound heliquinomycin was first identified as 
an inhibitor of in vitro replication in cell extract systems (Chino et al. 1996), and was later 
shown to inhibit the DNA unwinding properties of a Mcm467 (Ishimi et al. 2009). In cell 
culture, heliquinomycin has been shown to selectively decrease the proliferation of cancer 
cells overexpressing Mcm7 (Toyokawa et al. 2011). 
 A second compound, Widdrol, was observed to have antiproliferative activity 
against human colon adenocarcinoma HT29 cells (Kwon et al. 2010). Interestingly, this 
effect appeared to be due to a downregulation of Mcm gene expression as a downstream 
consequence of DNA damage. While not a direct effect, it does further validate the use of 
compounds that reduce Mcm availability or activity as chemotherapeutic agents.  
1.3 STRUCTURAL INSIGHTS INTO MCM2-7’S FUNCTION 
Structural biological studies of the Mcm complex fall into two broad categories. The first is 
high resolution studies of X-ray crystallography structures of Mcm subunits and complexes 
isolated from Archaeal organisms. These studies are useful in they show us atomic 
resolution of the complex, but have limited applicability to eukaryotes as they are not 
highly conserved with eukaryotic Mcms outside the C-terminal domain containing the 
AAA+ active site and helicase motifs, and there are fundamental differences in archaeal 
DNA replication, which only have one Mcm protein and lack accessory factors necessary 
in eukaryotes like GINS and CDC45. 
16 
The second category is low-resolution structures determined with electron 
microscopy techniques. This includes 3-dimensional reconstructions of dodecamers of the 
archaeal mcm complex, and hexamers of the eukaryotic Mcm2-7 as well as larger 
complexes (CMG and OCCM) from single particle image averaging of electron 
microscopy images. These recent structures have proved invaluable in confirming 
predicted protein interactions. 
Table 1 List of published Mcm structural papers 
Organism Resolution Notes Ref. 
S. pombe N/A Rotary shadowing of complexes 
isolated from cell extracts 
(Adachi et al. 1997) 
Human N/A 2D EM of individual Mcm467 
hexamers 
(Sato et al. 2000) 
M. thermautotrophicus 3 Å Crystal structure of N-terminal 
fragment, packs as a dodecamer 
(Fletcher et al. 2003) 
M. thermautotrophicus 25 Å Single particle reconstruction of 
dodecamer, open and closed rings 
observed 
(Gomez-Llorente et al. 2005) 
M. thermautotrophicus 24 Å 3D reconstruction of dodecamer (Costa et al. 2006a) 
M. thermautotrophicus N/A 2D analysis of MtMCM with various 
ligands, evidence of both double and 
single  hexamers/heptamers 
(Costa et al. 2006b) 
M. thermautotrophicus 25 Å DNA bound to outside of single 
hexamer 
(Costa et al. 2008) 
S. sulfolobus 2.8 Å Crystal structure of an N-terminal  
fragment, packs as a hexamer 
(Liu et al. 2008) 
S. sulfolobus 4.35 Å Crystal structure of near full length 
Mcm monomer 
(Brewster et al. 2008) 
M. kandleri 1.9 Å Full length crystal structure of a 
nonfunctional Mcm homologue 
(Bae et al. 2009) 
D. melanogaster 28,32,35Å EM single particle reconstruction of 
CMG complex, and closed and open 
Mcm hexamers 
(Costa et al. 2011) 
Human N/A NMR structure of the C-terminus of 
Mcm6 bound to Cdt1 
(Liu et al. 2012) 
E. cuniculi 24 Å Mcm from a minimalist eukaryote. 
Forms an open hexamer even in the 
presence of ATP 
(Lyubimov et al. 2012) 
S. cerevisiae  14 Å CryoEM structure of OCCM 
complex containing Mcm2-7 
(Fernandez-Cid et al. 2013) 
 
The earliest electron microscopy analyses of Mcm2-7 (Adachi et al. 1997) and 467 
(Sato et al. 2000)  were our first indication that the Mcm complex forms a toroid, which 
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when combined with the knowledge that the complex elutes off gel filtration columns at 
approximately 600 kDa yielded the initial evidence that the eukaryotic Mcms are 
hexameric helicases. 
1.3.1 Archaeal Structural Studies 
It wasn’t until the crystal structure of the N-terminal portion of the Methanothermobacter. 
thermautotrophicus archaeal Mcm that we had physical confirmation that the Mcm 
proteins can form hexameric toroids. Although this initial structure lacked the C-terminal 
(and much more highly conserved) helicase domain, it still demonstrated the toroid had a 
positively charged central channel sufficiently large to accommodate DNA, and also 
demonstrated that the archaeal Mcm hexamers are able to pack against each other at the N-
terminus, forming a dodecamer with oppositely facing complexes. This raised the 
possibility that the functional form of the Mcm complex may be a double hexamer at one 
or more stages of the cell cycle. This possibility was supported by electron microscopy 
single particle reconstructions of the full length M. thermautotrophicus Mcm complex 
(Gomez-Llorente et al. 2005; Costa et al. 2006a), which showed the full length protein 
forming a dodecamer. Conversely, a crystal structure of the equivalent N-terminal portion 
of the archaeal Mcm from S. sulfolobus packs as a hexamer. Given the high degree of 
variability of the N-terminal region of the Mcms, even within archaea, it remains unclear 
how applicable these structures are to the eukaryotic Mcm complex. 
Later crystallographic analyses of the full length S. sulfolobus and M. kandleri 
Mcms provided the first views of the Mcm helicase domain. Several features distinguish 
the Mcms among other helicases. 
 18 
 Figure 4: Mcm structural motifs in S. sulfolobus 
Adapted from (Bochman and Schwacha 2009) with the permissions granted by the American 
Society of Microbiology. PreS2: Presensor 2, S2: Sensor2, N-T hp: N-terminal hairpin, WB: Walker B motif, 
RF: Arginine Finger motif, Zn Finger: Zinc Finger, H2I hp: Helix-2-insert hairpin, PS1 hp: Presensor 1 
hairpin, Ext hp: External Hairpin, WA: Walker A motif, S1: Sensor 1, ACL: allosteric control loop. 
 
Figure 4 depicts the near full length structure with notable motifs highlighted in 
color. Absent is the Winged Helix domain, which is disordered and not visible. Many of 
these motifs have been analyzed for their role in the complex’s helicase activity. As 
expected (McGeoch et al. 2005), and consistent with other AAA+ ATPases (Erzberger and 
Berger 2006) Walker A and B motifs are present on the cis side of the intersubunit active 
interface, along with the Sensor 1 motif, while the trans side of the monomer contributes 
the arginine finger and Sensor 2 motifs. The trans acting Sensor 2 motif is a feature unique 
to the Mcms, as it functions in cis in other AAA+ proteins. This difference is a result of the 
Presensor 2 insertion found in the Mcm helicase clade (Erzberger and Berger 2006). 
Several β fingers depicted in the structure have been shown to be important for 
DNA binding and helicase activity of archaeal Mcm complexes and have been proposed to 
be in physical contact with the DNA substrate. In the N-terminus, the N-terminal hairpin 
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extends into the central channel, and has been shown to be important for the complex’s 
ssDNA binding capabilities (McGeoch et al. 2005). 
In the C-terminus two additional hairpins extend into the central channel. The first 
is the  Presensor 1 insert, found to be moderately important for ssDNA binding, but is 
essential for archaeal helicase activity (McGeoch et al. 2005). The second is Helix 2 insert, 
which is the unique and defining feature of the Mcm helicase superfamily, and has been 
shown to be essential for coupling ATPase activity to DNA unwinding (Jenkinson and 
Chong 2006).  
One remaining hairpin lies near a conserved side channel (per pair of monomers) in 
the S. sulfolobus structure. While a biological role for this side channel has not yet been 
demonstrated, the external hairpin is involved in DNA binding (Brewster et al. 2008) 
All of these structural motifs are conserved in the eukaryotic Mcms to varying 
extents, however, evidence suggests that, like the active sites motifs, they are not all 
functionally equivalent. An example of this is the Presensor 1 and 2 motifs of Mcm3. 
Sequence alignment of the Mcm proteins show that Mcm3 alone has an extensive insertion 
within the Presensor 2 motif that is conserved across multiple species (Bochman and 
Schwacha 2009) and represents one of the few areas of sequence divergence in the AAA+ 
domain among the six Mcm proteins.  Functional differences are also seen in the Presensor 
1 motif, as only the presensor 1 motif from Mcm3 is essential for viability and helicase 
function (Lam et al. 2013). 
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1.3.2 Eukaryotic Structural Studies 
Structural analyses of the full eukaryotic Mcm2-7 complex have to date been limited to 
electron microscopy reconstructions. The first 3D model of the eukaryotic replicative 
helicase was reported by Costa et al., in a comprehensive analysis of the Drosophila 
melanogaster Mcm2-7 complex (Costa et al. 2011). As expected, the complex forms a 
hexameric toroid, with a central channel large enough to bind ssDNA. Furthermore, they 
confirmed the subunit order predicted from biochemical studies (see Figure 2) through the 
use of MBP fusion tags.  
Most importantly, the 3D structure confirmed many of the mechanistic predictions 
made by prior biochemical DNA binding studies (Figure 5). The apo form of the complex 
appears to exist in an equilibrium between two discrete states. The first is a right handed 
spiral ‘lockwasher’ with an open gap between Mcm2 and Mcm5, and second a planar 
notched form. 
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 Figure 5: Conformational states of the Drosophila Mcm complex 
Panels A and B: The Drosophila Mcm2-7 complex exists two discrete states, a planar notched form 
and a right handed lockwasher form. C) Addition of Cdc45 and GINS forms the CMG complex, which 
restricts the Mcms into the planar notched state D) Addition of ADP·BeF3 tightens the ring in the CMG 
complex, as shown by the narrowing of the space between Mcm2 and Mcm5. Adapted from (Costa et al. 
2011) with the permission of Nature Publishing Group. 
 
 It had previously been determined that the functional form of the replicative 
helicase requires the accessory factors Cdc45 and GINS (Moyer et al. 2006; Ilves et al. 
2010), forming an 11-protein CMG complex. Interestingly, it appears that the binding of 
these factors and a non-hydrolysable analogue serve to close the ring, supporting the 
hypothesis that gate closure is how the Mcms are activated. 
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While the CMG complex represents the biochemically active state of the Mcm 
complex, a recent structure of a Pre-RC intermediate, the ORC-Cdc6-Cdt1-Mcm2-7 
(OCCM) complex was recently isolated from yeast and its structure determined with cryo-
EM (Sun et al. 2013). Key differences arise when comparing this structure with that of the 
CMG complex (Figure 6). 
 
Figure 6: S. cerevisiae Mcm2-7 in the OCCM complex 
Shown are the Mcm2-7 and Cdt1 components of the OCCM complex, (ORC and Cdc6 not 
pictured). The (?) designates unexpected positive density determined to be co-purifying DNA. Adapted from 
(Sun et al. 2013) with the permission of Nature Publishing Group. 
 
Sun et al. (Sun et al. 2013) found that the subunit order of the S. cerevisiae Mcm 
complex was consistent with what was seen in the D. melanogaster structure and predicted 
biochemically. Of note is the state of the Mcm2/5 active site, which lacks the large 
discontinuity seen in the Costa et al. structure (Costa et al. 2011). Unexpectedly, the 4/6 
active site seems to have a slight discontinuity. The implications of these discrepancies will 
be discussed below. 
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1.3.2.1 Double VS Single hexamer 
A long standing question has been whether the functional state of the Mcm complex is a 
single or double hexamer. Given the observation that M. thermautotrophicus assembles as 
a double hexamer in crystal and EM structures, and the observation of double hexamers of 
the eukaryotic Mcms bound at origins (Evrin et al. 2009; Remus et al. 2009; Gambus et al. 
2011), several models were originally proposed which suggested that the active unwinding 
complex could either split as two hexamers from a single origin, or stay together and 
function as a dodecamer (Brewster and Chen 2010)., However, recent single molecule 
studies have confirmed that the functional form of the eukaryotic Mcm complex during S-
phase is a single hexamer (as part of the CMG complex) operating by the steric exclusion 
model (Yardimci et al. 2010; Fu et al. 2011; Yardimci et al. 2012) while the loaded form 
(as part of the Pre-RC complex) is a double hexamer (Remus et al. 2009).  
1.3.2.2 The Mcm Gate: Discrepancies between species and structures 
The recent structures of Mcm2-7 in D. melanogaster (Costa et al. 2011), S. cerevisiae (Sun 
et al. 2013), and E. cuniculi (Lyubimov et al. 2012) display a slight discrepancy with the 
previous literature. While they all indicate a role for gate dynamics, they do not quite 
conform to the ATP-dependence and activity states that have been shown biochemically 
(Bochman and Schwacha 2008). The D. melanogaster Mcm2-7 appears to be dynamically 
shifting between open and notch states, and requires CDC45, GINS, and ATP for full 
closure. Costa et al report a minor shift in the apo structure’s propensity for the notched 
form in the presence of non-hydrolysable ATP analogues (Costa et al. 2011), but not to the 
degree predicted from S. cerevisiae DNA binding data (Bochman and Schwacha 2007; 
Bochman and Schwacha 2008). E. cuniculi also has a visible gate in the presence of ATP 
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analogues. Conversely, the preRC intermediate OCCM structure isolated from G1 extracts  
shows the gate to be nearly closed, despite the fact that Mcm2-7 should be biochemically 
inactive at this stage of the cell cycle. 
What is the reason for these differences? One obvious possibility is species specific 
differences. Neither D. melanogaster nor E. cuniculi Mcm2-7 have been shown to have in 
vitro helicase activity alone. It has been assumed that proper assay conditions have not yet 
been discerned for these species as they have in S. cerevisiae (Bochman and Schwacha 
2008), but alternatively this could indicate fundamental biochemical differences in the 
complex in different organisms. 
Another explanation is that the regulation of the complex via the Mcm2/5 gate is 
more complicated than simply an ‘open and shut case’ and the gate opens and closes at 
multiple points in the cell cycle depending on Mcm2-7’s binding partners. 
Finally, we must also consider differences in purification protocol. Sun et al. 
included a high salt wash step, which is expected to dislodge any loosely bound Mcms 
(Sun et al. 2013). It’s conceivable that this step enriched their purification for Mcms found 
in the closed state bound to DNA. 
 
1.4 THESIS OVERVIEW 
The goal of my dissertation research has been to understand the role the Mcm2/5 gate plays 
in Mcm2-7’s function as the replicative helicase. Toward this end I have operated under 
the central hypothesis that disrupting the gate should have functional consequences, as well 
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as the reverse hypothesis that some of the previously characterized functionally deficient 
Mcm mutants have aberrant gate function. To test these hypotheses I investigated two 
independent, but complementary, specific aims.  
The first has been the identification and characterization of small molecule 
inhibitors of the Mcm2-7 complex. The second has been the structural characterization of 
the S. cerevisiae Mcm2-7 apo structure and Mcm mutants predicted to disrupt the Mcm2/5 
gate.  
1.4.1 Specific Aim 1: Identification and characterization of small molecule 
inhibitors of Mcm2-7 
The goal of this study was to address the possibility of finding an inhibitor specific to the 
regulatory active sites of Mcm2-7, which we reasoned could be identified by assaying for 
compounds that inhibit Mcm2-7 but not Mcm467 or Large T-antigen. The fluoroquinolone 
ciprofloxacin had been shown to be a likely starting candidate, and I assayed a variety of 
related fluoroquinolone and other structurally related compounds for greater selectivity 
and/or potency. After identifying promising candidates, I characterized their effects on 
ATPase activity, DNA intercalation, and assessed their effects on cells in vitro, ultimately 
identifying a ciprofloxacin resistant allele of Mcm4. 
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1.4.2 Specific Aim 2: Structural characterization of mutants effecting the Mcm 2/5 
‘gate’ 
Evidence for the Mcm2/5 gate has now been presented biochemically and structurally, but 
without a phenotype to attribute to the gate’s malfunction, its role in the cell cycle remains 
largely speculatory. Furthermore, there are discrepancies between the biochemical and 
structural literature regarding conditions that contribute to gate opening and closure, 
possibly due to species differences. To address these issues, I used single particle 
reconstruction to solve the structure of the S. cerivisiae in the apo state, along with mutants 
predicted to be open or closed based on DNA binding assays, and regulatory mutant, 
mcm5bob1, which bypasses the need for the regulatory kinase DDK for entry into S-phase. 
My findings show agreement between the biochemical and structural data for the state of 
the gate in S. cerevisiae, and support a role for the gate in S-phase entry.   
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2.0  MATERIALS AND METHODS 
2.1 DNA OLIGONUCLEOTIDES, CHEMICALS, ANTIBODIES, AND OTHER 
REAGENTS 
Oligonucleotides were all purchased from IDT. pUC19 DNA was purchased from New 
England Biolabs. 
Radiolabeled ATP was purchased from either MP Biomedical or Perkin Elmer Life 
Sciences. Nucleotides were purchased from GE Healthcare. All chemicals purchased for 
use in buffers and assays were of the highest available purity. 
Stock solutions of putative inhibitors were made in anhydrous DMSO at either 13 
mM (MAL2-11B (Wright et al. 2008)) or 100 mM (N-ethoxy-carbonyl-2-ethoxy-1,2-
dyhydroquinolone (EEDQ; Aldrich), N,N’-dicyclohexylcarbodiimide (DCCD; Sigma), 
pyridoxal 5’-phosphate (PP; Fluka), phenylglyoxal (PG; Aldrich), 4-chloro-7-
nitrobenzofurazan (Nbf; Fluka), ofloxacin (Sigma) and ciprofloxacin (Fluka, > 98% pure 
by HPLC)). N-ethylmaleimide (NEM, USB) was made as a 1M stock in absolute ethanol. 
These stock solutions were stored at -20°C and were stable for at least several months.  All 
compounds were completely soluble at the final assay concentrations except as noted.  
For initial small molecule inhibitor screening, a collection of 144 compounds was 
obtained from the Drug Discovery Center (DDC, University of Cincinnati, Cincinnati, OH) 
(Appendix). For follow-up experiments on selected inhibitors (Table 2), neat samples of 
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each inhibitor were obtained from DDC or ChemBridge (compounds 924384 and 271327 
correspond to ChemBridge 7473736 and 5281925, respectively) and stored as 100 mM 
stock solutions in DMSO. The purity of these compounds was either established by the 
manufacturer or was determined by the DDC using mass spectrometry and HPLC analysis 
and found to be >90-100% in all cases (Table 2). 
2.2 BUFFERS 
The following list is organized as follows: 
 Name of the buffer  Description of buffer’s purpose Buffer recipe 
1. Binding Buffer: Used in ssDNA binding assays and for dilution of samples prior to 
electron microscopy. 25 mM potassium-HEPES, pH7.4, 50mM KCl, 10mM 
MgOAc, 50 µM ZnOAc, 100 µM EDTA (pH 8.0), 10% glycerol, 0.02% NP-40, 
1mM DTT  
2. 2X Helicase Buffer Used in helicase and ATPase assays: 40 mM Tris-HCl pH 7.5, 
20mM MgOAc, 40% glycerol, 200 µM EDTA 10mM DTT 
 
3. 10X Stop load buffer: Loading dye used in quenching helicase assays an 
subsequent electrophoresis. 0.25% Bromophenol Blue, 0.25% Xylene Cyanol, 1% 
SDS, 100mM EDTA (pH 8.0), 25% Ficoll type 400. 
4. Tris/Borate/EDTA Buffer (TBE) Native PAGE.  90 mM Tris base, 90 mM borate, 
2mM EDTA, adjust pH to 8.0 
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5. Tris Buffered Saline+Tween 20 (TBST), 10X stock Western Blotting. 50 mM Tris,
150 mM Nacl, 0.05% Tween 
6. Topoisomerase Buffer For assaying DNA intercalation with topoisomerase II 50
mM Tris-HCl (pH 8), 1 mM EDTA, 1 mM DTT, 20% glycerol, and 50 mM NaCl.
2.3 PROTEIN PURIFICATION 
Hexameric S. cerevisiae Mcm2-7 and Mcm467 complexes were expressed in baculovirus-
infected insect cells, and purified using affinity, gel filtration, and ion exchange 
chromatography as described (Bochman and Schwacha 2007; Bochman et al. 2008)Gel 
filtration and Western blot analysis indicates that the complexes contain equimolar 
amounts either all three (i.e., Mcm467) or all six (i.e., Mcm2-7) of the indicated Mcm 
subunits. The Simian Virus 40 large tumor antigen (TAg) was purified as previously 
described (Cantalupo et al. 1999). Additional helicases were generously provided by 
colleagues: the SsoMcm complex (M. Trakselis, University of Pittsburgh, Pittsburgh, PA); 
Srs2 (E. Antony, Washington University School of Medicine, St. Louis, MO); T7 gp4 (S. 
Patel, University of Medicine and Dentistry of New Jersey, Piscataway, NJ); DnaB (K. 
Marians (Sloan-Kettering, New York, NY); and T4 gp41 (S. Benkovic, Pennsylvania State 
University, University Park, PA).  
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2.4 METHODS 
2.4.1 In vitro Helicase Assay 
Helicase assays were performed as described previously, (Bochman and Schwacha 2007; 
Bochman and Schwacha 2008), except when inhibitors were used in which case the 
incubation time was increased from 30 minutes to one hour. Synthetic replication forks 
were prepared by annealing oligos 233 and 235 (IDT (Coralville, IA), oligo 233 
5’ (T)40GGTTGGCCGATCAAGTGCCCAGTCACGACGTTGTAAAACGAGCCC; 
oligo 235 5' CACTCGGGCTCGTTTTACAACGTCGTGACTGGGCACTTGATCGG-
CCAACC(T)40) and then filling in the recessed 3’-end with [a32P]dATP and 
unlabeled dNTPs using Klenow Fragment. Briefly, reactions (6 µL) were performed in 
1x helicase assay buffer (20 mM Tris HCl (pH 7.5), 10 mM MgOAc, 20% glycerol, 100 
µM EDTA, and 5 mM DTT) and contained a final concentration of 1 nM fork substrate, 
5 mM ATP, 40 mM creatine phosphate, 16.5 mg/mL creatine kinase, 33 µg/mL BSA. 
Reactions containing Mcm2-7 and Mcm467 were supplemented with 200 mM potassium 
glutamate. Reactions containing SsoMcm were incubated at 65°C, those containing T4 
gp41 were incubated for 30 min at 37oC, and all other reactions were incubated at 37°C 
for 1 h. The products were separated by 10% native PAGE, the resulting gels dried, and 
the radioactivity quantified using a Fuji FLA-5100 phosphoimager. Irrespective of the 
protein used, all helicase assays contained equal molar protein concentrations (100 nM, 
assuming in all cases that the active helicase form is hexameric).  
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2.4.2 DNA Binding assay 
Single stranded DNA binding assays were performed as described (Bochman and 
Schwacha 2007). The single stranded DNA substrate was a mixed 50mer probe, oligo 826 
TGTCTAATCCCGAAAGGCCCTGCCACTGAAATCAACACCTAAAGCATTGA,  
radiolabeled at the 5’ end with T4 polynucleotide kinase (New England Biolabs) and (γ32P) 
ATP. Standard reactions contained 4nM unlabeled oligonucleotide 826 spiked with a small 
amount of labelled probe, 120 nM Mcm hexamers, 5mM ATPγS, and 5mM β-
glycerophospate in binding buffer. Reactions were incubated for 30 minute at 30 degrees 
C.  
Double filter binding with nitrocellulose and DEAE filters was performed as described 
(Wong and Lohman 1993). Prepared filters were stacked on a GE healthcare FH 225V 
Filter Manifold and washed with 500 µL of binding buffer. Reactions were spotted on the 
filter stack, washed with an additional 500 µL of binding buffer, then the radioactive 
counts on DEAE and nitrocellulose filters were measured separately by scintillation 
counting. Percent DNA bound was calculated as the number of radioactive counts on the 
nitrocellulose filter divided by the total counts on both filters. 
2.4.3 Steady State ATPase assay 
Steady-state ATP hydrolysis was assayed as published (Schwacha and Bell 2001). In short, 
reactions were set up essentially as in the helicase assay, with minor exceptions. A non-
radiolabeled DNA fork was used, helicase concentration was 100 nM (hexamer) the total 
ATP concentration was 500 µM and included ~0.5 µCi of [a32P]ATP, and the ATP 
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regeneration system was omitted. Reactions were incubated for 1 h at 37°C and stopped by 
the addition of SDS. ATP was separated from ADP by PEI thin layer chromatography, and 
the ratio of ATP:ADP was quantified with a Fuji FLA-5100 phosphoimager. Based upon 
our prior work (Schwacha and Bell 2001), conditions were established to ensure that the 
results shown are within the linear range of the assay 
2.4.4 Topoisomerase Assays 
Topoisomerase assays were adapted from (Jones-Held 1992). Reactions (10 µL) contained 
were carried out in topoisomerase buffer and containing pUC19 (50 ng; NEB) was 
incubated at 37°C for 2.5 h with 4 units of Wheat Germ Topoisomerase I (Promega). 
Inhibitors were added at the indicated concentrations at either t=0 or t=90 min as described 
in the figure legends. Following incubation, topoisomers were separated via gel 
electrophoresis on a 1.0% agarose gel for 2 h at 8 V/cm in TAE buffer. After 
electrophoresis, the gel was stained with ethidium bromide and imaged with a Fuji LAS-
3000. In all of the above assays, dilutions of the test compound were made with Milli-Q 
H2O and DMSO such that the final concentration of DMSO in the biochemical assays was 
1% (v/v), and the reported activity was normalized to solvent controls. 
2.4.5 Yeast Growth inhibition assay 
S. cerevisiae growth inhibition was quantified using an established 96-well plate assay 
(Simon et al. 2000). Two isogenic W303 testers strains were used (construction details 
available upon request): UPY675 (matA, ade2-1, ura3-1, his3-11,15, trp1-1, leu2-3,112, 
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can1-100, bar1::hisG, Derg6:: kanMX) and UPY1056 (isogenic to UPY675 but containing 
mcm4chaos3). Overnight yeast cultures were grown in YPD, diluted to 0.05 OD600, grown 
to an OD600 of 0.1-0.15, aliquoted into a 96-well plate, and then treated with inhibitor 
titrations. Inhibitors were first diluted in pure DMSO, then added to wells to a final volume 
of 100 µL containing 2% DMSO. Plates were grown without shaking at 30oC for 24 h. 
Optical density was quantified at 0 and 24 h with a Bio-tek EL800 Universal Microplate 
reader. Percent relative growth was determined by calculating the change in optical density 
over 24 h at each concentration relative to a 2% DMSO control. 
2.4.6 Yeast membrane permeabilization assay 
Due to the difficulty of doing genetics with ∆erg6 strains, some replication mutants were 
tested using an assay adapted from (Pannunzio et al. 2004), which renders wild type yeast 
permeable to small molecules when grown in the presence of sodium dodecyl sulfate 
(SDS) and L-proline instead of ammonium sulfate as the nitrogen source. Strains were 
grown overnight in synthetic media with appropriate amino acids, 0.17% yeast nitrogenous 
base, 0.1% L-proline, and 2% glucose. The following day the cultures would be diluted to 
0.15 OD in fresh media containing 0.003% SDS and allowed to recover for 3 hours before 
challenging with inhibitors. 
2.4.7 Graphing and statistical analysis 
Inhibition and the corresponding 95% confidence intervals (CIs) from both the helicase 
assays and growth inhibition assays were plotted using GraphPad Prism Version 5.0f for 
34 
Macintosh. The inhibitor concentrations were converted to Log10, and then nonlinear 
regression was used to fit the data points with a sigmoidal dose-response curve using the 
following equation: 
 
where ymin is the minimum helicase activity, ymax is the maximum helicase activity, 
IC50 is the effective concentration of inhibitor that decreased helicase activity by 50%, and 
the Hill Slope describes the steepness of the curve. In all cases, the equation was 
constrained by subtracting the baseline from the data and normalizing all values to helicase 
activity in the absence of inhibitor. Thus, ymin and ymax were 0 and 100%, respectively. 
The software was also used to calculate the 95% CIs, the quality of the fit (i.e., R2), and to 
determine the extra sum-of-squares F test to calculate P values to compare the LogIC50 
values between curves. Differences in values were considered statistically significant when 
P < 0.05. 
2.4.8 Electron Microscopy Sample Preparation 
Purified Mcm proteins were diluted to approximately 50ng/µL in binding buffer. A 10 µL 
drop of dilute protein was spotted onto a piece of Parafilm and was adsorbed for 30-60 s to 
a glow-discharged (Quorum Emitech K100X Glow Discharger) carbon coated grid 
(Formvar backed 400-mesh carbon, Ted Pella 1702-F)  held with fine tip tweezers. The 
excess liquid was gently wicked onto a piece of Whatman paper, and the grid was 
transferred to a 100 µL drop of 1.5% uranyl acetate for 30 s. The excess liquid was once 
again wicked away and the grid was allowed to air dry. 
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Certain protein preparations had a tendency to lay on the grid in a preferred 
orientation, leading to an overrepresentation of certain views. In these cases, additional 
views of the complex were obtained by increasing the glycerol concentration of the 
dilution buffer (binding buffer) to 20%. Under these buffer conditions a 70 kelvin cryo 
holder was use to protect the sample from damage during imaging.  
Images taken for optimizing staining conditions were taken on a FEI Morgagni 
microscope operating at 80kv at the listed magnifications. Images were taken with an 
Advanced Microscopy Techniques XR-60 digital camera. 
Images for model building were taken on a Tecnai TF20 transmission electron 
microscope operating at 200kv, at nominally 29000X magnification in low dose mode. 
Images collection was done in Digital Micrograph with a Gatan Ultrascan 4000 CCD 
camera with a post column magnification of 1.4 and CCD elements of 15 µm dimensions. 
The effective pixel size was 3.7 Å.  
2.4.9 EMAN Single Particle 3D reconstruction. 
All final model building was done using the EMAN2 image processing suite 
(http://blake.bcm.edu/emanwiki/EMAN2) (Tang et al. 2007) Version 2.07. For all steps 
command strings were built using the e2projectmanager interface, and parameters and 
arguments referred in this section based on how they are organized in the interface for each 
module. 
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2.4.9.1 Particle Import and CTF tuning 
Raw image files were initially CTF corrected and imported into EMAN2 with e2eval.py. 
For this step, the parameters for voltage, area/pixel, and spherical aberration from the 
microscope used to collect data were specified (200kV, 3.7, and 2 respectively for the 
Tecnai TF20). Amplitude contrast was set to 0.7 and a box size of 512 pixels was used for 
the initial CTF tuning. Initial CTF tuning was performed by roughly adjusting the defocus 
parameter so that the graph of the contour transfer function aligned with the phase of the 
power spectrum. Micrographs were imported without contrast inversion. 
Particles were collected semi automatically using the swarm function in 
e2boxer.py. The box size used was the nearest ‘good box size’ that was roughly 1.5 the 
width of the Mcm complex (100 angstroms). This generally was 168, depending on which 
version of EMAN2 was used for particle picking.  
CTF tuning was done on the selected particles with e2ctf.py with the default 
parameters, except the amplitude contrast was increased to 70 as is appropriate for negative 
stain.  After generating a structure factor, particles were CTF tuned again, manually 
corrected, then exported as phase flipped particles. 
At this stage particles were analyzed on a micrograph by micrograph basis, and 
poor particles (those poorly centered, too small, or too close to other particles) were 
rejected for particle set building. Particle sets of varying sizes were assembled, generally 
smaller sets (less than 10,000 particles) were used for reference free class averaging and 
initial model building, and larger sets (20,000-40,000 particles) where used for further 
model refinement. In cases where high glycerol conditions were used to increase 
representative views of the complex, the smaller particle set would contain roughly equal 
numbers of particles collected under ‘high glycerol’ and standard conditions. 
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2.4.9.2 Reference free class averaging 
Reference free class averages were constructed in e2refine2D.py by generating an 
appropriate amount of classes depending on particle set size and the thresholding level 
(generally 50%), such that approximately 10-20 particles were generated per class average, 
typically resulting in 300-500 classes. Generally, the only parameters adjusted when 
optimizing reference free class averages where the total number of particles in the particle 
set, the number of class averages, and the thresholding level. 
For the refine2d parameter options, typically fast seeding was used when generating 
a greater than 100 class averages, and normalized projection vectors were not used unless a 
marked improvement in class averages were seen with its usage. Eight iterations were done 
during each refinement. The number of alignment references (naliref) and the number of 
MSA basis projection vectors (nbasisfp) where each set to the default value of 5.   
Under simmx options, the shrink factor was set to a value of 3 and an oversampling 
to a value of 2. The comparator (simcmp) used to align the images was the cross 
correlation coefficient (ccc) and the aligner used prior to comparing the images (simalign) 
was rotate_translate_flip. Finally, the aligner along with construction arguments 
(simaligncmp) was the cross correlation coefficient (ccc). Second stage alignment was not 
used in reference free class averaging. 
For class averaging options, the level of thresholding was varied to experimentally 
to see what resulted in optimal classes. Initially, the default level of 0.85 would be used 
and lowered on subsequent refinements, with optimal results generally obtained with a 
level of 0.5. For each refinement, five iterations were performed. For class normalization 
(classnormproc) ‘normalize.edgemean’ was used. The class averager used was ‘mean,’ 
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class comparator (classcmp) used was ‘ccc,’ the class aligner (classalign) was 
‘rotate_translate_flip’, and the first stage comparator used was ‘ccc.’ 
Once optimal reference free class averages were defined, 20-30 selected class 
averages representing different views of the Mcm toroid were saved as a .hdf image stack. 
2.4.9.3 3D modeling 
The selected class averages were used to generate a roughly toroidal initial model with 
e2initialmodel.py, as determined by Z-slices through the generated volume. Eight iterations 
and ten tries were performed for each round of modeling, with C1 symmetry (no 
symmetry) applied. 
Refinement of the initial model was done in e2refine.py against the phase flipped 
particle set. Once conditions were established that lead to convergence on a solution, 
refinement was done iteratively until successive iterations failed to improve the model. 
Options used in e2refine.py varied as model building progressed. 
Under ‘e2refine options’ the area per pixel for all refinements was 3.6 angstroms, 
the particle mass was 600 kDa (estimated mass of the Mcm2-7 complex). The number of 
iterations and parallel processors were varied depending on available computational 
capabilities.  
For ‘e2refine model options’ the best previously generated model (either an initial 
model or a model from a previous refinement) was used as the refinement seed. Auto Mask 
3D was used in all refinements, with the default parameters (threshold=0.8, radius=30, 
mask dilations=5, Gaussian dilations=5, NMax=30). 
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Under ‘e2project options’ the projecter used was ‘standard’, the orientation 
generation argument (orientgen) used was EMAN, with the parameters 
delta=5.0:inc_mirror=0:perturb=1 and model was assigned the  C1 symmetry group. 
For ‘e2simmx options,’ a shrink factor of 3 was used for early refinements, and 
reduced to 1 when refining higher quality models to obtain higher resolution. When 
shrinking was used, a shrink factor of 2 was applied to the two stage similarity matrix. The 
simmx comparator (simcmp) used was Fourier Ring Correlation (frc) with the parameters 
zeromask=1:snrweight=1. The simmx aligner (simalign) used was rotate_translate_flip, 
and the comparator used by the first stage aligner (simaligncmp) was ccc. The number of 
classes a particle could contribute was restricted to 1 (sep=1). 
Several options were varied under ‘classaverage options,’ depending on the quality 
of the seed map and the particle set. Class iteration was set to 5 for initial model 
refinements, then reduced to 1 when improving resolution. The class averaging threshold 
was varied similar to the reference free class averaging step. The normalization processor 
for class averaging (classnormproc) was ‘normalize.edgemean.' The classaverager used 
was ‘mean.’ The comparator used to compute similarity scores (classcmp) was ‘frc’ with 
options zeromask=1:snrweight=1. For multiple iterations, the class average aligner 
(classalign) was rotate_translate_flip. The comparator used by the first stage aligner 
(classaligncmp) was ccc. For speed purposes, second stage alignments generally were not 
used unless the referenced class averages generated were poor, in which case the second 
stage aligner was set to ‘refine’ with the comparator ‘dot.’ 
Under ‘e23dmake’ options, the only parameter that was varied between refinements 
was the m3dkeep parameter, which is the fraction of 3d slices kept during modeling, and 
was varied from 0.3 to 0.85. The number of iterations was held constant at 2. The 
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reconstructor used was fourier, and the ‘pad’ parameter was the ‘good box size’ (defined in 
the EMAN2 supporting documentation) that was closest to 125% the size of the boxsize 
used to pick particles, generally 196. No post processing arguments were used within 
e2refine.py 
2.4.9.4 Resolution, filtering, and final map generation. 
Resolution was calculated using the FSC method using the 0.5 criterion using e2eotest.py. 
This was achieved by running the e2eotest.py command string with identical arguments 
used to generate the model (see 2.4.8.3), with two additional arguments: path=refineXX, 
where XX is the number of refinement resolution is being estimated for, and iter=X, which 
specifies the iteration within that refinement. Most maps refined to final resolution of 
approximately 25 angstroms 
 Molecular graphics of EM maps were generated in UCSF Chimera (Pettersen et al. 
2004). For all structures, a low pass Gaussian filter was applied and the isosurface 
threshold was adjusted such to equivalent mass specific volumes, assuming a protein 
specific density of 1.35gm/cm3. 
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3.0  CIPROFLOXACIN AND RELATED COMPOUNDS ARE INHIBITORS OF 
THE MCM2-7 COMPLEX 
The contents of this chapter, with some additions and modifications, come from (Simon et 
al. 2013), per our retained copyright. Nicholas Simon conducted this work with the 
following exceptions: Matthew Bochman performed the initial experiments summarized in 
Figure 7. Sandlin Seguin purified the SV40 Large T antigen (TAg) and performed the 
human cell culture experiment under the direction of Jeffrey Brodsky. William Seibel 
assembled and provided the small molecule library and verified the purity of individual 
compounds. Anthony Schwacha supervised the conduct of the experiments of Nicholas 
Simon and Matthew Bochman. 
3.1 SUMMARY 
Most currently available small molecule inhibitors of DNA replication lack enzymatic 
specificity, resulting in deleterious side effects during use in cancer chemotherapy and 
limited experimental usefulness as mechanistic tools to study DNA replication. Toward 
development of targeted replication inhibitors, we have focused on Mcm2-7, a highly 
conserved helicase and key regulatory component of eukaryotic DNA replication.  
Unexpectedly we found that the fluoroquinolone antibiotic ciprofloxacin preferentially 
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inhibits Mcm2-7.  Ciprofloxacin blocks the DNA helicase activity of Mcm2-7 at 
concentrations that have little effect on other tested helicases and prevents the proliferation 
of both yeast and human cells at concentrations similar to those that inhibit DNA 
unwinding.  Moreover, a previously characterized mcm mutant (mcm4chaos3) exhibits 
increased ciprofloxacin resistance. To identify more potent Mcm2-7 inhibitors, we 
screened molecules that are structurally related to ciprofloxacin and identified several that 
compromise the Mcm2-7 helicase activity at lower concentrations. Our results indicate that 
ciprofloxacin targets Mcm2-7 in vitro, and support the feasibility of developing specific 
quinolone-based inhibitors of Mcm2-7 for therapeutic and experimental applications. 
3.2 INTRODUCTION 
As cancer cells demonstrate uncontrolled proliferation relative to most non-cancer 
cells, DNA replication has traditionally been an important target for cancer chemotherapy. 
Such therapeutics are frequently nonspecific and mutagenic, as they either chemically 
modify the DNA to block replication fork progression or trap deleterious topoisomerase 
II/DNA double strand break intermediates (Hurley 2002). Not surprisingly, these therapies 
have multiple toxic side effects (reviewed in (Zhou and Bartek 2004)). Newer 
topoisomerase inhibitors, which inhibit the catalytic activity of the enzyme rather than 
trapping the toxic protein-DNA intermediate, show therapeutic promise (Nitiss 2009), 
suggesting that compounds that specifically inhibit DNA replication enzymatic activity 
may be better suited as therapeutic agents. Moreover, enzyme inhibitors have had a long 
and important history in biochemical research, and their use has been an essential avenue 
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to obtain critical mechanistic insight (e.g., the F1 ATPase (Vignais and Lunardi 1985)).  As 
eukaryotic DNA replication is a complex process that is poorly understood at a mechanistic 
level, the development of targeted small molecule inhibitors of specific replication factors 
would be of significant research utility. 
One potential therapeutic target is the Mcm2-7 eukaryotic replicative helicase, a 
molecular motor that unwinds duplex DNA to generate ssDNA templates for replication. 
Unlike other replicative helicases, the toroidal Mcm2-7 complex is formed from six 
distinct and essential subunits, numbered Mcm2 through Mcm7 (Bochman and Schwacha 
2009). Each subunit is an AAA+ ATPase, and the unique heterohexameric composition of 
this helicase is conserved throughout eukaryotic evolution (reviewed in (Bochman and 
Schwacha 2009)). Consistent with its vital function during DNA replication, Mcm2-7 is a 
key target of regulation, as its loading is a carefully controlled and limiting feature of 
replication initiation, while its cell cycle-dependent activation is a limiting feature of 
elongation (Bell and Dutta 2002). The importance of its regulation is demonstrated by the 
observations that both specific mutations in Mcm2-7 (Kawabata et al. 2011) and over 
expression of its subunits (Honeycutt et al. 2006) cause cancer or contribute to 
tumorigenesis. Despite the potential of helicases as disease targets, few specific small 
molecule inhibitors of these enzymes have been identified (Crute et al. 2002; Ali et al. 
2007; Wright et al. 2008; Tani et al. 2009). To date, one compound, heliquinomycin, has 
been identified that inhibits a non-physiological Mcm subcomplex (Mcm467) (Ishimi et al. 
2009) and decreases the proliferation of cancer cells in vitro (Toyokawa et al. 2011), 
further suggesting that Mcm inhibitors may have therapeutic value. 
Following examination of amino acid modifiers and small molecule ATPase 
inhibitors (Vignais and Lunardi 1985; Ali et al. 2007; Wright et al. 2008), we found that 
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the commercially available fluoroquinolone antibiotic ciprofloxacin preferentially inhibits 
the in vitro helicase activity of the Saccharomyces cerevisiae Mcm2-7 complex. 
Ciprofloxacin also appears to target Mcm2-7 in cell culture, as it blocks proliferation of 
both yeast and human cells at concentrations that inhibit the purified enzyme, and a 
previously studied cancer-causing mutation in Mcm4 confers ciprofloxacin resistance 
(Shima et al. 2007). Additional inhibitors of greater potency were identified among 
compounds structurally related to ciprofloxacin. Several of these agents exhibited 
increased selectivity toward Mcm2-7, while others had varying specificities against a range 
of unrelated helicases. These data suggest that (fluoro)quinolone-based compounds may 
provide a general scaffold for future development of helicase inhibitors with targeted 
specificity 
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3.3 FLUOROQUINOLONES BLOCK MCM HELICASE ACTIVITY 
A variety of amino acid modifiers were initially tested. These chemical probes covalently 
modify carboxyl groups (carbodiimide derivatives EEDQ and DCCD), guanidyl groups 
(PG), amino groups (PP), phenol groups (Nbf), and thiol groups (NEM) and have been 
previously used to study the ATPase active sites in the F1-ATPase (reviewed in (Vignais 
and Lunardi 1985)). Although most of these amino acid modifiers inhibited all three 
helicases, DCCD had no effect (Figure 7A, treatment 3), and PG (Figure 7A, treatment 5) 
preferentially inhibited Mcm2-7 and Mcm467, suggesting the unique role of one or more 
accessible arginines in the Mcm complexes, possibly the external β-hairpin, a motif which 
is lacking in SV40 TAg and contains a conserved arginine (see Figure 2 in (Bochman and 
Schwacha 2009)). 
The effects of several previously identified helicase inhibitors were also examined. 
The pyrimidinone-peptoid hybrid molecule MAL2-11b and the fluoroquinolones ofloxacin 
and ciprofloxacin have been previously reported to inhibit various TAg-mediated activities 
(Ali et al. 2007; Wright et al. 2008). MAL2-11b inhibited all three helicases to a similar 
extent at 1 mM (Figure 7A, treatment 8), but little or no inhibition of TAg helicase activity 
was observed with 1 mM ciprofloxacin or ofloxacin (Figure 7A, treatments 9 and 10; 
however inhibition was observed at higher concentrations, see below). In contrast, 1 mM 
ciprofloxacin inhibited the helicase activity of both Mcm2-7 and Mcm467 (Figure 7A, 
treatment 10).  
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 Figure 7: Identification of Mcm2-7 inhibitors 
A) Inhibition of helicase activity. Helicase assays were conducted as described in the Materials and 
Methods chapter, The indicated proteins (TAg, Mcm2-7, Mcm467), at 100 nM concentration, were 
preincubated with the indicated small molecules (treatments 2-10) for 20 min at 37°C prior to addition of 
ATP and the DNA substrate. For each panel: +, boiled DNA fork; -, intact fork; 0, reconstituted helicase 
assay without small molecule; 1, standard assay containing 1% DMSO. Treatments 2-10 are reconstituted 
helicase assays additionally containing 1 mM of the following compounds: 2, EEDQ; 3, DCCD; 4, PP; 5, PG; 
6, Nbf; 7, NEM; 8, MAL2-11b; 9, ofloxacin; and 10, ciprofloxacin. B) With SV-40 T-antigen, prior ATP 
preincubation protects from inhibition. This experiment was identical to A), except that the indicated helicase 
was preincubated with 5 mM ATP for 20 min at 37°C prior to addition of inhibitor and DNA substrate. The 
discontinuities in these gel images, denoted by a vertical line between treatments 8 and 9, indicates the 
location where an irrelevant treatment in the assay was electronically removed. C) The small molecules have 
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variable effects on ssDNA binding. Filter binding assays were conducted as described in Materials and 
Methods using 150 nM of the indicated helicase.  For TAg-(A), Mcm2-7 and Mcm467, the indicated helicase 
was incubated with the small molecule prior to ATP addition as in A); for TAg-(B), TAg was preincubated 
with ATP prior to small molecule addition as in B). D) Small molecule inhibition of helicase ATPase 
activity.  ATPase activity was assayed as described in Materials and Methods using 100 nM final helicase 
concentration. The treatment numbering in C) and D) are identical to those in A). The data in Figure 7C 
represent the average of ≥2 experiments, and the error bars represent the range or standard deviation, as 
appropriate. The data in Figure 7D represent the average of ≥3 experiments, and the error bars represent the 
standard deviations. 
 
 
 
Because TAg subunits oligomerize only in the presence of ATP (Gai et al. 2004), 
and ATP preincubation likely causes a conformational change in Mcm2-7 (Bochman and 
Schwacha 2007; Bochman and Schwacha 2008), we also tested the effects of the potential 
inhibitors after the proteins were preincubated with ATP (Figure 7B). Although this 
treatment had essentially no effect on either Mcm complex, it completely or partially 
protected TAg from all modifiers except Nbf (Figure 7B, treatment 6) and MAL2-11b 
(Figure 7B, treatment 8), suggesting that at least one effect of the other inhibitors may be to 
block TAg oligomerization. 
Because helicase activity depends upon ATP hydrolysis and ssDNA binding, the 
effects of the chemical modifiers and small molecules on both activities were examined. 
Using previously established steady-state ATP hydrolysis (Schwacha and Bell 2001) and 
ssDNA filter binding (Bochman and Schwacha 2007) assays, the effect of the same panel 
of small molecules on each of the three helicases was examined. With the exception of 
DCCD and ofloxacin, which failed to inhibit helicase activity, most of the remaining 
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treatments severely inhibited the ATPase activities of all three helicases (Figure 7C). These 
data suggest that the inhibition of DNA unwinding is mediated by compromised function 
of one or several ATPase active sites. However, these small molecules caused a less severe 
and variable decrease in TAg ssDNA binding regardless of the order of ATP addition. 
Conversely, Nbf, NEM, and MAL2-11b did inhibit Mcm2-7 and Mcm467 ssDNA binding 
(Figure 7D, treatments 6-8). Ciprofloxacin stands in sharp contrast: Even though it 
completely inhibited Mcm helicase activity, it had only modest effects on ATP hydrolysis 
and ssDNA binding of the three helicases (Figure 7C and D, treatment 10). Collectively, 
these results suggest that ciprofloxacin inhibits a step or steps specifically required for 
DNA unwinding, possibly through selective inhibition of the Mcm regulatory subunits.  
3.4 CIPROFLOXACIN SHOWS SELECTIVITY FOR MCM2-7 
We quantified the IC50 values of ofloxacin and ciprofloxacin on Mcm2-7, Mcm467, and 
TAg helicase activity. We found that very high concentrations of ofloxacin inhibited both 
Mcm2-7 and Mcm467 with similar IC50s (Figure 8A): 4.17 mM (95% CI = 3.31-5.26 mM) 
and 5.29 mM (95% CI = 4.92-5.69 mM), respectively while the apparent IC50 of ofloxacin 
for TAg was much higher (>20 mM; Figure 8A). In contrast naladixic acid, the parent 
quinolone compound for both ciprofloxacin and ofloxacin, had essentially no effect on the 
activities of the three helicases at any concentration tested (data not shown). 
Interestingly, ciprofloxacin inhibited Mcm2-7 at an approximately 3-fold lower 
concentration than Mcm467 (Mcm2-7 IC50=632 µM, 95% CI=552-723 µM; Mcm467 
IC50=1.89 mM, 95% CI=1.24-2.87 mM, respectively; Figure 8B) and at an approximately 
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6-fold lower concentration than TAg (IC50=4 mM, 95% CI=2.91-5.53 mM). This 
selectivity of ciprofloxacin for Mcm2-7 relative to TAg supports the proposal that Mcm-
specific inhibitors may be found. In addition, the selectivity of ciprofloxacin for Mcm2-7 
relative to Mcm467 supports the proposal that active site-specific inhibitors of the Mcm 
complex can be identified. 
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 Figure 8: Two fluoroquinolones show preference for the Mcm helicases 
The inhibitor effects of either ofloxacin A) or ciprofloxacin B) were tested on the DNA unwinding 
activity; the indicated helicases were all used at a final concentration of 100 nM following preincubation with 
inhibitor. The results were quantified and converted to % activity relative to the respective activity in the 
absence of inhibitor. All reactions contained 1% solvent (DMSO). 
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3.5 A LIBRARY SCREEN OF SMALL MOLECULE INHIBITORS 
We reasoned that other (fluoro)quinolone derivatives might show enhanced Mcm2-7 
specificity at potentially lower inhibitor concentrations. As the fluoroquinolones are used 
as antibiotics (reviewed in (Collin et al. 2011)), prior drug discovery efforts have resulted 
in the synthesis of chemically diverse libraries modeled on key elements found in the basic 
fluoroquinolone scaffold. Therefore, we investigated a 144-compound chemical library that 
contained either (fluoro)quinolone derivatives or molecules with various substructures 
found in ciprofloxacin and other marketed quinolones. 
This library of 144 compounds was initially screened for inhibition of Mcm2-7, 
Mcm467, and TAg helicase activity at a final concentration of 1 mM (see Appendix for 
chemical structures and a complete list of results). Of the compounds tested, 27 
reproducibly inhibited at least one of the three helicases to ≥90%. Both (fluoro)quinolone 
and triaminotriazine-like inhibitors were identified. Although a wide range of results were 
obtained, two general conclusions emerged from the data 1) Few molecules exhibited 
robust inhibition of TAg, and those that did (e.g., 924384, 125248, and 486369) also 
inhibited Mcm2-7 and Mcm467; and 2) many molecules demonstrated at least partial 
inhibition of Mcm2-7 with little or no inhibition of TAg. Interestingly, although some of 
the inhibitors appeared to inhibit both Mcm2-7 and Mcm467, the relative strength of this 
inhibition varied. One agent appeared to act like ciprofloxacin and preferentially inhibited 
Mcm2-7 (314850), while others appear to preferentially inhibit Mcm467 (e.g., 502432 and 
502423).  
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3.6 SELECT LIBRARY COMPOUNDS DISPLAY GREATER POTENCY AND 
SELECTIVITY THAN CIPROFLOXACIN 
In addition to ciprofloxacin, seven representative compounds from among those described 
above were chosen for additional study based either upon potency, selectivity, 
reproducibility, dose-dependent effect, and/or availability. Figure 9 summarizes their 
effects on the DNA unwinding activity of TAg, Mcm2-7, and Mcm467, again at a final 
concentration of 1 mM. To provide a quantitative measure of inhibitor affinity and 
selectivity, fresh samples of known purity (>90%) were obtained for each of the seven 
inhibitors, and the IC50 values for DNA unwinding were determined for all three helicases. 
In most cases, these compounds were either more potent or more selective than 
ciprofloxacin (Figure 10 and Table 2). Based upon their differential inhibition of the three 
helicases, the inhibitors were classified into one of two groups: 
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 Figure 9: Effects of select (fluoro)quinolone inhibitors on A) TAg helicase, B) Mcm2-7, and C) 
Mcm467 activity. 
For each panel: +, boiled DNA fork; -, intact fork; 0, solvent control; 1, compound 125248; 2, 
924384; 3, MAL2-11b; 4, 268973; 5, 388612; 6, 314850; 7, 271327; and 8, ciprofloxacin. Inhibitors were 
added to a final concentration of 1 mM, as in Figure 7. The values below the gels indicate the percent of 
DNA unwinding by the indicated helicase normalized to the solvent control (treatment 0). 
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The first was General inhibitors. These inhibitors that had approximately equal 
effects on all three helicases include MAL2-11b (Figure 9) and compounds 125248, 
924384, 268973, and 388612 (Table 2). Interestingly, unlike any of the (fluoro)quinolones 
characterized, the triazole 924384 and the structurally related compound 388612 were 
more effective at inhibiting TAg than either Mcm complex (Table 2). The IC50 values for 
each of these compounds are similar to one another and ranged from ~50-400 µM. 
The second was Mcm-selective inhibitors. Two inhibitors (271327 and 314850) fall into 
this category. The fluoroquinolone 271327 inhibited both Mcm complexes with an IC50 of 
~300-450 µM but had a negligible effect on TAg within the concentration range tested 
(Figure 10). Although the limited solubility of 271327 prevented us from testing higher 
concentrations, we can conclude that the IC50 against TAg is at least an order of 
magnitude greater than that of the Mcm complexes. In contrast, 314850 preferentially 
inhibited Mcm2-7 relative to Mcm467 but had little effect on TAg. 
Table 2 Structures and IC50 values of selected inhibitors 
 IC50 µM* 
Inhibitor Structure Source
‡ 
(purity) Yeast Human Mcm2-7 Mcm467 
T-
antigen 
Ciprofloxacin 
N
O O
OH
F
N
HN
 
Fluka 
(>98%, HPLC) 
590 
(520-
670) 
240 
(160-350) 
632 
(553-
723) 
1890 
(1240-
2870) 
4010 
(2910-
5530) 
MAL2-11b 
HN
N CH3O
O
O
O
OH
 
J. 
Brodsky 
(>99%, 
evaporative 
light scattering 
and UV 
spectroscopy 
(Wright et al. 
2008)) 
ND ND 
96 
(47-193) 
112 
(56-226) 
192 
(144-
256) 
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125248 
(Bouzard et 
al. 1992) 
F
N
CH3
N
O
OH
O
NH2N
 
DDC-UC 
(>90%, 
HPLC/MS) 
460‡ 
14 
(6-30) 
72 
(52-100) 
130 
(113 - 
151) 
190 
(180-
201) 
924384 
(Kumar et al. 
2008) 
N
N
N
N N
H
HN
HN  
ChemBridge 
7473736 
(>90%, NMR) 
93 
(67-
130) 
10‡ 
115 
(105-
127) 
246 
(226-268) 
70 
(56-87) 
268973 
O O
N
Cl
N
OH
OH
H2N
 
DDC-UC 
(>90%, 
HPLC/MS) 
160 
(37-
730) 
ND 
188 
(154-
229) 
272 
(234-316) 
476 
(364-
622) 
388612 N
NN
HN
CH3  
DDC-UC 
(>90%, 
HPLC/MS) 
<10 
nM‡ ND 
396 
(284-
551) 
345 
(304-391) 
126 
(84-
188) 
271327 
(Domagala 
et al. 1991) 
NN
O
HN F
F
ONH2
OH
 
ChemBridge 
5281925 
(>90%, NMR) 
700‡ 
210 
(67-650) 
361 
(294-
444) 
460 
(394-538) 
> 1000 
314850 N
S
N
O
H2N H3C
OH
O
H
 
DDC-UC 
(>90%, 
HPLC/MS, 
NMR) 
520 
(400-
690) 
340 
(150-740) 
261 
(219-
312) 
707 
(579-865) 
> 1000 
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 Figure 10: The identified inhibitors exhibit diverse specificities against different helicases 
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3.7 MECHANISM OF INHIBITION BY CIPROFLOXACIN RELATED 
COMPOUNDS 
As noted above, DNA unwinding is the culmination of a variety of simpler biochemical 
activities. Thus, the seven representative inhibitors and ciprofloxacin may function by 
physically interacting with the helicase, the DNA substrate, or the ATP. To understand 
how all eight inhibitors block helicase activity, their effects on steady-state ATP hydrolysis 
were measured (Figure 11A). Relative to MAL2-11b, which completely inhibits ATP 
hydrolysis of Mcm2-7, Mcm467, and TAg (Figure 7C (treatment 7) and 11A (treatment 
3)), both the general and Mcm-selective inhibitors demonstrated only a modest inhibition 
of ATP hydrolysis (e.g., 268973; Figure 11A, treatment 4), while several demonstrated 
essentially no inhibition of ATP hydrolysis (e.g., 314850 and 271327; Figure 11A, 
treatment 6 and 7).  
These results suggest one of three possible scenarios: First, the inhibitors (with the 
possible exception of MAL2-11b) might not target the ATPase active sites. Second, the 
inhibitors may deregulate or uncouple the activity of the enzyme rather than block ATP 
hydrolysis. Third, at least in the case of the Mcm2-7 complex, the inhibitors could 
preferentially target the ATPase active sites but are selective for the low-turnover 
regulatory sites. Although the second and third possibilities are difficult to distinguish, the 
first explanation can be tested. While we cannot rigorously test for competitive inhibition 
using our helicase endpoint assay, we can test if increased ATP concentration overcomes 
the inhibitory effects of these compounds (Figure 11B). Although doubling the ATP 
concentration in the absence of inhibitor caused a slight increase in helicase activity (1.5 to 
2-fold, Figure 11B, treatment 0), in most cases, doubling the ATP concentration in the 
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presence of the inhibitors caused a much larger increase in activity (3 to 20-fold). These 
results suggest that the inhibitors disrupt ATPase active sites in the Mcm2-7 complex in 
some manner. In contrast the inhibitory effects of 924384, MAL2-11b, and 268973 could 
not be rescued by an increase in ATP concentration (Figure 11B treatments 2-4), 
suggesting that these inhibitors operate independently of the ATPase active sites. 
Because these compounds are also planar double ring molecules, they could 
conceivably inhibit helicase activity via DNA intercalation. To examine this model, we 
tested our inhibitors in a standard topoisomerase assay (Jones-Held 1992).  The rationale of 
this assay is that intercalating compounds will introduce supercoils into a fully relaxed 
plasmid. Topoisomerase I (Topo I) will remove these introduced supercoils, but after 
quenching and gel electrophoresis the intercalator will diffuse away and produce a 
detectable compensatory supercoiling increase. 
 Following plasmid relaxation, each inhibitor was added to 1 mM final 
concentration in the topoisomerase assay (Figure 11C, treatments 1-8). The general 
inhibitors 125248 (treatment 1), 924384 (treatment 2), 268973 (treatment 4) and 388612 
(treatment 5) cause extensive DNA intercalation, while in contrast, MAL2-11b (treatment 
3) and the more Mcm-selective inhibitors (314850, 271327, and ciprofloxacin, treatments 
6-8) demonstrated little or no intercalation (Figure 11C). However, lack of apparent 
intercalation could also be caused by Topo I inhibition. To test this possibility, the assay 
was repeated under conditions in which Topo I and each inhibitor were added to the 
reaction at the same time. Under these conditions, Topo I inhibition will only yield 
supercoiled plasmids (Figure 11D). Under this criterion and comparing the results to 
Figure 11C, only MAL2-11b (Figure 11D, treatment 3) is a Topo I inhibitor. Although the 
general inhibitors can intercalate into dsDNA at 1 mM concentration (Figure 11C), in vitro 
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helicase inhibition occurs at much lower inhibitor concentrations. Repeating the 
intercalation assay at more modest inhibitor concentrations (2-3 fold over calculated IC50 
for helicase inhibition) only 125248 and 268973 continued to demonstrate significant DNA 
intercalation (Figure 11E, treatments 1 and 4). Thus, most of the tested inhibitors, 
including ciprofloxacin, do not appear to function through intercalation, suggesting that 
they more directly affect the helicase activity.  
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Figure 11: Mode of action of the various small molecule inhibitors 
Treatment order for each panel: 0, solvent control; 1, compound 125248; 2, 924384; 3, MAL2-11b; 
4, 268973; 5, 388612; 6, 314850; 7, 271327; and 8, ciprofloxacin. A) Effects of each inhibitor on steady state 
ATP turnover by Mcm2-7, Mcm467, and TAg. This experiment was identical to that shown in Figure 7C 
with the indicated helicase used at 100 nM concentration, but 1 mM of the indicated inhibitor was added 
prior to ATP addition. Bar graphs show the levels of ATP hydrolysis observed after 30 min of incubation as a 
% of the ATP hydrolysis observed in the absence of inhibitor (treatment 0). B) Effect of increased ATP 
concentration with indicated inhibitor on DNA unwinding activity of Mcm2-7. The standard helicase reaction 
was supplemented with the indicated inhibitor concentration (numbered 1-8 as in A) in the presence (+) or 
absence of an additional 5 mM ATP.  ATP and the indicated inhibitor were added together to Mcm2-7 
without preincubation. “Fold” refers to the ratio of DNA unwinding between the reactions containing 10 mM 
ATP and containing 5 mM ATP. C) Ability of inhibitors to intercalate into DNA. In the intercalation assay 
(Materials and Methods), Topo I (4 units) was used to relax 50 ng of monomeric pUC19 (treatment 0; 
compare supercoiled DNA (left) with relaxed DNA (right)). After 1 h of Topo I treatment, 1mM of the 
indicated inhibitor was added and samples were incubated for an additional 1 h D) Topo I activity inhibition 
assay. This experiment was identical to C), except that Topo I and the indicated inhibitor were added at the 
same time. Topo I inhibition is indicated if addition of both inhibitor and topoisomerase together generates 
supercoiled DNA, while experiments shown in C) generate relaxed plasmid. E) An intercalation assay 
performed with the indicated inhibitors at lower concentrations. These assays were similar to C) (Topo I 
added first, and the inhibitor added second), except the indicated concentration of inhibitor was used. 
3.8 CIPROFLOXACIN IS NOT A GENERAL HELICASE INHIBITOR 
An ideal Mcm2-7 inhibitor would specifically target this helicase both biochemically and 
in living cells. To test this hypothesis, these properties were assayed in the following 
experiments. 
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To further define inhibitor selectivity, we examined their in vitro effects on 
representative helicases at 1mM concentration (Figure 12). Inhibitors 125248, 924384, and 
268973 (treatments 1-3) were the least specific, causing nearly complete inhibition of 
DnaB and T4 gp41. Interestingly, only one additional inhibitor (314850, treatment 6) 
effectively inhibited the SsoMcm complex. This discrepancy may be due to the high assay 
temperature (65°C) required to assess SsoMcm helicase activity(McGeoch et al. 2005). 
Inhibitor 271327 (treatment 7) caused substantially less inhibition among the helicases 
tested than either 125248 or 924384.  In contrast, none of the tested helicases were 
substantially inhibited by ciprofloxacin (Figure 12, treatment 8). Combined with the IC50 
data summarized in Table 1, Mcm2-7 is the only helicase tested that is preferentially 
inhibited by ciprofloxacin.  
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 Figure 12: Ciprofloxacin poorly inhibits hexameric helicases unrelated to the Mcms. 
All inhibitors were used at 1 mM final concentration. Lane order for each panel: +, boiled DNA 
fork; -, intact fork; 0, solvent control; 1, compound 125248; 2, 924384; 3, MAL2-11b; 4, 268973; 5, 388612; 
6, 314850; 7, 271327; and 8, ciprofloxacin. The helicase tested is listed at the top of each gel, and the percent 
of helicase activity remaining in the presence of inhibitor is listed below each gel. The reaction conditions 
used for each helicase are similar to that used for Mcm2-7 and described in the Experimental Procedures. The 
values below the gels indicate the percent of DNA unwound by the indicated helicase normalized to the 
solvent control (treatment 0). 
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3.9 CIPROFLOXACIN AND LIBRARY COMPOUNDS INHIBIT YEAST AND 
HUMAN CELL GROWTH 
To examine the general cellular toxicity of these inhibitors, growth inhibition of 
micro-cultures by serial dilution of inhibitors was tested in a 96-well format in yeast 
(Simon et al. 2000). Wild type yeast is resistant to ciprofloxacin (Figure 13A). However, 
resistance to many compounds in yeast reflects an inability to accumulate sufficient 
concentrations of such compounds due to the prevalence of multidrug transporters 
(reviewed in (Balzi and Goffeau 1995)). To circumvent this potential problem, we used a 
yeast mutant (∆erg6) (Welihinda et al. 1994) previously shown to non-specifically 
decrease drug resistance. As anticipated, this strain had demonstrable growth sensitivity to 
both ofloxacin and ciprofloxacin (Figure 13A).  
 
Figure 13: Fluoroquinolone sensitivity: Wild Type VS ∆erg6  
∆erg6 cells show demonstrable sensitivity to fluoroquinolones.  
 
 
Using the ∆erg6 strain, the remaining compounds were tested for growth inhibition 
over a range of concentrations (Figure 14, Table 2). Several compounds inhibited growth at 
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lower concentrations than they inhibited in vitro helicase activity (388612, 268973, and 
924284), suggesting that proteins other than Mcm2-7 are more sensitive to inhibition. 
These data are consistent with their poor helicase selectivity as demonstrated above. In 
contrast, several compounds were less efficient at inhibiting yeast growth than helicase 
activity (125248 and 314850). However, two inhibitors (ciprofloxacin and to a lesser extent 
271327) have IC50 curves that closely match the IC50 curves for Mcm2-7 helicase activity 
(Figure 17, Table 2), consistent with the possibility that the primary cellular target is 
Mcm2-7. 
Inhibitor cytotoxicity was next examined in a non-tumor human cell line (RPE-
TERT, Figure 14). In general, these cells were demonstrably more sensitive to the tested 
inhibitors than yeast. RPE-TERT cells were ~10-fold more sensitive to 125248 and 924384 
(IC50s of about 10 µM) than 271327 and 314850 (IC50s ~500-700 µM). The extreme 
sensitivity of human cells to both 125248 and 924384 suggests that Mcm2-7 is not a major 
cellular target. In contrast ciprofloxacin kills human cells and inhibits yeast growth at 
roughly similar concentrations (i.e., human cells are only ~ 2.5 fold more sensitive than 
yeast). 
 66 
 Figure 14: Sensitivity of yeast and human cells to inhibitors 
Representative assays are shown, and were performed as described in Chapter 2.4.8. The results are 
normalized to growth in the presence of 1% DMSO. 
3.10 IDENTIFICATION OF AN MCM MUTANT THAT CONFERS 
CIPROFLOXACIN RESISTANCE 
While the above data were consistent with Mcm inhibition in cells, the same could be said 
for any replication protein. To address if the Mcm complex was the cellular target, we first 
tested to see if overexpression of the Mcm complex was sufficient to confer ciprofloxacin 
resistance. ∆erg6 cells were transformed with three integrating plasmids bearing the six 
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MCM genes under bidirectional GAL inducible promoters. Although all six MCMs were 
successfully overexpressed, no difference could be seen between in the IC50s of cells 
overexpressing the construct and regular ∆erg6 cells (Figure 15). Similar results were 
obtained expressing the Mcms individually and in pairs. 
 
Figure 15: MCM overexpression does not confer ciprofloxacin resistance 
All 6 Mcm subunits were overexpressed in the ∆erg6 background. The IC50 levels were 
indistinguishable from the parent strain.   
 
Given the difficulties of creating ∆erg6 double mutants, a variety of Mcm and DNA 
replication mutants were initially screened against W303 yeast utilizing a growth 
conditions that render the yeast permeable to small molecules. After verifying that we have 
similar sensitivity to ciprofloxacin under these conditions, we observed that while the 
viable ATPase active site mutants were indistinguishable from wild type, the checkpoint 
mutants and Mcm4-Chaos3 showed slight resistance (Figure 16).   
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 Figure 16: MCM mutants tested in permeabilized yeast 
 
To rule out variability from the assay, we constructed a double mutant 
∆erg6Xmcm4chaos3 strain, and found that this slight resistance to Ciprofloxacin was 
retained. (Figure 17) (∆erg6 IC50: 590 µM (95% CI=520-670 µM) vs. ∆erg6 
mcm4chaos3:1300 µM (95% CI=1200-1400 µM). Combined with the data described 
above, we conclude that Mcm2-7 is a ciprofloxacin target.  
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 Figure 17: The Mcm4chaos3 mutation confers ciprofloxacin resistance. 
In yeast, cellular growth and in vitro helicase activity is impaired with nearly identical concentration 
dependence. Mcm4chaos3 mutants demonstrate increased resistance to ciprofloxacin. In all graphs, 
the data represent the average of ≥3 experiments, and the error bars represent the standard 
deviations. 
3.11 DISCUSSION 
We provide evidence that ciprofloxacin (and to a lesser extent compound 271327) 
inhibits the activity of the budding yeast Mcm2-7 helicase both biochemically and in cell 
culture. Although our experiments largely focus on yeast, we also demonstrated that 
ciprofloxacin inhibits the viability of human cells at roughly similar concentrations. As 
fluoroquinolones have been extensively used in human medicine and their pharmacological 
properties are established (Collin et al. 2011), the fluoroquinolone scaffold might well 
serve as a useful platform in the development of Mcm2-7 inhibitors with enhanced 
therapeutic potential. Although inhibition of Mcm2-7 occurs at ciprofloxacin 
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concentrations higher than its normal therapeutic range (also see below), our results 
suggest that some of the side effects seen with this and other fluoroquinolones may be due 
to inhibition of DNA replication.  
 
3.11.1 Relationship to prior studies 
Fluoroquinolones serve as potent antibiotics due to their strong inhibition of the 
prokaryotic DNA gyrase. Although eukaryotes are relatively resistant to ciprofloxacin at 
normal therapeutic levels, cytotoxicity is noted at high drug concentrations (reviewed in 
(Collin et al. 2011)). The eukaryotic topoisomerase II enzyme is a target for 
fluoroquinolones such as ciprofloxacin, as the drug inhibits topoisomerase II in vitro 
(Barrett et al. 1989), and mutants in topoisomerase II have been isolated with increased in 
vitro fluoroquinolone resistance (Elsea et al. 1995). Moreover, cells exposed to cytotoxic 
levels of fluoroquinolones arrest in G2 and demonstrate chromosomal breaks consistent 
with the known role of topoisomerase II in mitosis (Smart et al. 2008), However it should 
be noted that these are also relatively common phenotypes of various known DNA 
replication mutants (e.g (Hennessy et al. 1990)).  
Both our in vitro and cell-based studies strongly support Mcm2-7 as a new 
eukaryotic target for fluoroquinolones.  Our finding that the Mcm mcm4chaos3 mutant has 
significantly increased ciprofloxacin resistance provides evidence that at least part of 
fluoroquinolone cytotoxicity is likely due to defects in DNA replication. 
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3.11.2 Inhibitory effects of amino acid modifiers 
Although chemically reactive amino acid modifying agents are too unstable, non-
specific, and irreversible to assist in studies of Mcm2-7 in vivo, there is considerable 
precedence for using modifying reagents in vitro to determine a mode of action in complex 
systems (Vignais and Lunardi 1985). For example, DNA replication requires a large 
number of nucleotide hydrolases (e.g., ORC, Cdc6, Mcm2-7, RFC, primase, and DNA 
polymerases (Bell and Dutta 2002)), and knowledge of the inhibitory spectrum of 
modifiers on individual replication factors will aid future studies that examine functional 
interactions between these proteins. Because preincubation of TAg with ATP relieved 
much of the inhibitory effects of these modifiers (Figure 7B), they most likely affect ATP 
binding and oligomerization of TAg, which is ATP-dependent. One interesting difference 
between inhibition of the Mcms and TAg is with the guanidyl modifier phenylglyoxal 
(PG), which inhibits both Mcm2-7 and Mcm467 without affecting TAg. This property 
could make PG an experimentally useful reagent in vitro if Mcm2-7 activity needs to be 
specifically ablated. 
 
3.11.3 Mode of (fluoro)quinolone inhibition 
Our results suggest that most of the studied inhibitors likely interfere with the 
ATPase active sites of the helicases. Although these molecules only have a modest effect 
on bulk ATP hydrolysis of Mcm2-7 (Figure 11A), helicase inhibition is largely suppressed 
by increased ATP concentration (Figure 11B). The relatively high observed IC50 
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concentrations are consistent with this possibility, as the ATP Km0.5 for helicase activity by 
the yeast Mcm2-7 is ~2 mM (Bochman and Schwacha 2008). However, if 
(fluoro)quinolones act as inhibitors of ATPase active sites, how can the relatively minor 
inhibition of ATP hydrolysis be explained? 
For Mcm2-7, bulk ATP hydrolysis correlates poorly with DNA unwinding. There 
are mutations that cause substantial reductions in ATP hydrolysis but have only minor 
effects on in vitro DNA unwinding (e.g., Mcm3KA (Bochman and Schwacha 2008)), while 
other mutations retain robust steady state ATP hydrolysis but reduce in vitro DNA binding 
or unwinding (e.g., Mcm6DENQ (Bochman and Schwacha 2008; Bochman and Schwacha 
2010)). Only two of the Mcm2-7 ATPase active sites are responsible for most of the 
observed steady state ATP hydrolysis (i.e., the Mcm3/7 and 7/4 active sites (Davey et al. 
2003; Bochman et al. 2008)). 
 The remaining active sites, though clearly essential, hydrolyze ATP poorly. These 
data suggest that occupancy and turnover at these sites correspond predominately to a 
regulatory role rather than a direct contribution to helicase function. If the 
(fluoro)quinolone inhibitors preferentially target the regulatory rather than catalytic sites, 
only a modest change in ATP hydrolysis might be observed. Alternatively, the inhibitors 
may function to poison the helicase. By binding to a single active site, the inhibitor might 
uncouple ATP hydrolysis from DNA unwinding by altering the ability of adjacent active 
sites to communicate. 
 This model also explains the effect of these inhibitors on TAg, a homohexameric 
helicase that contains identical ATPase active sites that coordinately unwind DNA during 
SV40 replication (Gai et al. 2004). Finally, the fluoroquinolones could inhibit helicase 
activity by blocking ssDNA binding; however this interpretation is difficult to reconcile 
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with our observations that elevated levels of ATP restore Mcm2-7 helicase activity in the 
presence of most of the examined fluoroquinolones (Figure 11B). 
3.11.4 Prospects for tailoring fluoroquinolones as effective helicase inhibitors for 
Mcm2-7 
Helicases are abundant in eukaryotes. For example, in yeast, ~2% of open reading 
frames contain known helicase structural motifs (Shiratori et al. 1999). In addition to 
Mcm2-7, many human helicases (e.g., the RecQ family members such as the Werner, 
Bloom, and RecQ4 helicases, (van Brabant et al. 2000)) are also potential therapeutic 
targets. Given the paucity of available helicase inhibitors and our observations that 
different fluoroquinolones differentially inhibit a variety of helicases (Figure 12), 
fluoroquinolones may provide a general and malleable molecular scaffold for the 
development of efficient helicase inhibitors with tailored specificities.  
Further development of fluoroquinolones provides a useful route to develop Mcm2-
7-specific inhibitors of therapeutic value, as Mcm over expression correlates with cancer, 
and multiple studies indicate that the Mcm2-7 subunits are potential targets (Toyokawa et 
al. 2011; Suzuki et al. 2012). Several of the inhibitors that we examined (ciprofloxacin, 
271327 and 314850), demonstrate at least partial selectively for Mcm2-7 over a host of 
other helicases tested and ciprofloxacin appears to target Mcm2-7 in yeast. As 
ciprofloxacin and related fluoroquinolones are common and approved human antibiotics 
(Tanabe et al. 2000), this molecular scaffold has proven pharmaceutical utility. Although 
our inhibitors only act at concentrations that exceed typical therapeutic use, this situation 
has precedence. For example, high doses of sodium phenylbutyrate are used in the 
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treatment of malignant tumors, in which plasma concentrations of the compound are well 
over 1 mM (Phuphanich et al. 2005). Given the degree of selectivity that we observe with 
an off-the-shelf pharmaceutical designed for an entirely different application, our limited 
screen of ciprofloxacin-related compounds has identified several chemicals with improved 
properties, validating the likelihood that additional structural refinement using 
ciprofloxacin as a starting point will yield molecules with enhanced potency and 
specificity.  
Our discovery of Mcm2-7 inhibitors has utility in other areas. First, they may 
function as a useful research tool both in vitro and in vivo. As each of the six Mcm subunits 
are individually essential, analysis of the role of the replicative helicase has largely focused 
on model systems such as S. cerevisiae that have especially well developed genetic tools. 
Such inhibitors also have potential utility for biochemical studies, especially using systems 
(e.g., Xenopus egg extracts (Lebofsky et al. 2009)) that have highly tractable biochemical 
advantages but are poorly amenable to genetic manipulation. Second, the discovery that 
fluoroquinolones can inhibit the eukaryotic helicase may explain some of the cytotoxic 
effects observed with ciprofloxacin and other fluoroquinolones (Olcay et al. 2011). Our 
finding that the mcm4chaos3 allele confers resistance to ciprofloxacin supports our 
hypothesis that the Mcm2-7 complex is a ciprofloxacin target in cells and suggests that it 
could also be contributing to the deleterious side effects seen with this class of compounds. 
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4.0  STRUCTURAL ANALYSIS OF MUTANTS AFFECTING THE MCM 2/5 
‘GATE’ 
The experiments in this chapter were performed by Nicholas Simon under the supervision 
of Anthony Schwacha and James Conway. 
4.1 SUMMARY 
The replicative helicase is the molecular motor that unwinds double stranded DNA to the 
single stranded DNA substrate required by DNA replication machinery. In eukaryotes, this 
helicase is the CMG (CDC45, MCM, GINS) complex, which is comprised of 11 different 
subunits (Moyer et al. 2006). Six of these subunits are AAA+ ATPases, and form the 
Mcm2-7 complex, the replicative helicase’s catalytic core. This molecular motor holds the 
distinction of being the only hexameric helicase in which each of the six subunits are 
distinct and essential. Given that other hexameric helicases are oligomers of a single 
protein, this suggests that the six different Mcm subunits each contribute differently to the 
complex’s function. Numerous lines of evidence have shown that Mcm2 and Mcm5 form 
an ATP-dependent discontinuity, acting as “gate”(Bochman and Schwacha 2008; Costa et 
al. 2011) This discontinuity lends itself to the model in which Mcm loading is regulated by 
altering its topological state, physically opening the complex to load it onto origins of 
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replication and closing it to begin S-phase. However, there exists discrepancies among the 
published Mcm2-7 structures and biochemical literature regarding the state of the 2/5 gate 
in the presence of nucleotides and other binding partners. Furthermore, to date all functions 
for the Mcm gate have been purely speculatory, as there are no known viable mutants that 
have been positively shown to be defective for gate function. Toward addressing these 
questions, we have used single particle averaging from transmission electron micrographs 
to determine the structure of the S. cerevisiae Mcm2-7 complex in the apo state, along with 
mutants predicted to be open or closed based on our prior biochemical work. This was 
compared to structures of complexes containing mutations in certain AAA+ active site 
motifs. We found that the gate in the mutant complex mcm2DENQ, containing a mutation 
in the walker B motif, has a much narrower gate than the wild type complex, suggesting a 
structural cause for the mutant’s regulatory phenotypes in yeast. 
We also determined the structure of Mcm2-7 containing the bypass-of-block 
mutation in Mcm5, mcm5bob1, a proline to leucine mutation that bypasses the necessity of 
the essential regulatory kinase CDC7/DBF4(DDK), allowing for DDK-independent entry 
into S-phase (Hardy et al. 1997). Our results indicate that the mcm5bob1 mutation shifts 
Mcm5 into the Mcm2/5 gate in the complex’s open state. We propose that Mcm complexes 
containing mcm5bob1 protein is predisposed to a closed position, which is what allows it 
to bypass the need for DDK phosphorylation. Toward this end, we have used transmission 
electron microscopy and single particle averaging to compare wild type Mcm complexes 
with complexes containing mcm5bob1.  
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4.2 INTRODUCTION 
The faithful replication of DNA is a highly coordinated and regulated process.  Multiple 
chromosomes, each bearing multiple origins of replication, must be accurately replicated 
once, and only once, per cell cycle.  A major hub of this regulation is the Mcm2-7 complex 
(Bochman and Schwacha 2009).  
Mcm2-7, along with CDC45 and the four members of the GINS complex, form the 
eukaryotic replicative helicase (Moyer et al. 2006; Costa et al. 2011). However, unlike 
CDC45 and GINS, Mcm2-7 is associated with chromatin starting in early G1 phase, and its 
activity is regulated throughout the cell cycle. Multiple lines of evidence imply that the six 
different AAA+ active sites in Mcm2-7 play different roles in the regulation and enzymatic 
activity of the complex throughout the cell cycle. By separating the loading and DNA 
unwinding activities of the complex in different parts of the cell cycle, the cell is able to 
prevent replication errors from occurring. 
Specifically, Mcm2-7 is loaded onto origins of replication in early G1 phase by the 
loading factors CDC6 and CTF1. Together with the ORC complex these proteins form the 
Pre-Replication Complex (PreRC). In the Pre-RC the Mcms remain in a catalytically 
inactive state until the start of S-phase. Upon DDK and CDK dependent phosphorylation 
events, the Pre-RC is reorganized, loading factors are removed from the nucleus, GINS and 
CDC45 bind to the Mcm complex and DNA unwinding begins (reviewed in (Bochman and 
Schwacha 2009; Boos et al. 2012). 
Previous work has implicated that a topological discontinuity exists at the active 
site between two Mcm subunits, Mcm2 and Mcm5, forming an ATP-dependent “gate” 
(Bochman and Schwacha 2007; Bochman et al. 2008). Biochemically it appears this gate 
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must be closed in order for in vitro DNA unwinding to occur. We propose that this gate has 
an in vivo relevance, and that it is open during G1 to facilitate loading on to DNA and must 
be closed at the beginning of S-phase to initiate DNA unwinding.  
Several structures of Mcm2-7 with various ligands have recently been determined, 
each with different implications for the state of the Mcm2/5 gate. Costa et al. demonstrated 
that the Drosophila Mcm complex fluctuates between an open lockwasher and a notched 
planar ring in the apo state, and only the coordinated binding of ATP and the CMG 
components CDC45 and GINS are able to close the complex fully (Costa et al. 2011). 
A later structure of the Mcm2-7 from a minimalist eukaryote, E. cuniculi showed 
that the complex is in an open state upon nucleotide binding (the apo state was too 
heterogeneous to converge on a structure). E cuniculi is unusual in that while it has 
homologues of the members of the GINS complex it either lacks CDC45 entirely or it has 
diverged to the point where homology cannot be detected by sequence analysis, making it 
unclear if it has a complete CMG complex which could close the ring (Lyubimov et al. 
2012).  
Sun et al. provide the highest resolution structure to date of a eukaryotic Mcm 
complex in the structure of the higher order ORC/CDC6/CDT1/MCM (OCCM) complex 
(Sun et al. 2013), an pre-RC intermediate, determined with cryoEM, and is similar to the 
image averaged structure obtained by Remus et al. who observed a closed double hexamer 
bound around DNA (Remus et al. 2009).  
The goal of the study was to assess whether the gate has a physiological role by 
determining the structure of viable Mcm regulatory mutants we predict to have abnormal 
gate function. We found that the Mcm mutants mcm5bob1 and mcm2denq result in 
complexes biased toward a closed state relative to wild type complexes. 
 79 
4.3 OPTIMIZATION OF STAINING CONDITIONS 
Numerous conditions were explored to optimize negative staining of the Mcm 2-7 
complex. A wide variety of salt concentrations, buffer compositions, and heavy metal 
stains, namely uranyl acetate, uranyl formate, ammonium molybdate, and phosphotungstic 
acid, were tested and we ultimately determined that uranyl acetate provided the best 
staining conditions in our hands (Figure 18A). However, a large problem was 
heterogeneity of our protein samples. Some of this could be attributed to the dynamic state 
of the complex that has been shown previously (Bochman and Schwacha 2008; Costa et al. 
2011), however we also saw evidence of protein aggregates and loss of complex integrity.  
Initially we tried several strategies to improve the quality of our samples to enrich 
for functional hexamers. Small scale gel filtration was used to separate hexamers from 
smaller species, however this approach significantly diluted the sample and failed to 
remove protein aggregates (Figure 18B). 
Since most Mcm subassemblies fail to bind DNA (Bochman and Schwacha 2007), 
another approach was to use biotin-bound DNA oligonucleotides with a photocleavable 
linker, and incubate complexes with the DNA and ATPγS to enrich for functional 
hexamers that could bind DNA. However this approach also had problems with sample 
concentration (Figure 18C). 
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To address whether the heterogeneity problem was due to protein instability, we 
tested mild crosslinking conditions  Glutaraldehyde crosslinking showed some promise, 
and suggested that the problems with complex stability and misfolded proteins may have 
been arising during the staining process (Figure 18D). With this in mind, we were able to 
improve staining under non-crosslinking conditions by increasing sample concentration 
and reducing adsorption time, minimizing the time the complex spent in a dilute solution 
without the risk of potential artifacts introduced by crosslinking. 
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18 D) 
 
Figure 18 Optimization of protein samples for negative staining 
 85 
All samples were diluted in binding buffer then stained with 1.5% uranyl acetate. A) Standard 
staining conditions B) Pooled gel filtration fractions. Mcm2-7bob1 protein preparation was 
fractionated over a calibrated 1mL gel filtration column. Fractions containing hexamer-sized 
complexes were pooled and subjected to s standard staining conditions. C) DNA bound Mcms 
released by photocleaving. Mcms were bound to biotynlated oligonucleotide 825 in a standard 
binding reaction (See section 2.4.1) After the reaction was complete, 25uL streptavidin magnetic 
beads suspended in binding buffer were added to the reaction tubes. Tubes were placed on a tube 
rotator for 30 minutes, then placed into a magnetic rack and the beads allowed to settle, and the 
liquid drawn off. Beads were washed again in binding buffer, then exposed to UV light (254 nM) for 
1 minute by spotting the liquid onto saran wrap placed over a UV light box. Tubes were placed back 
in the magnetic rack, the liquid drawn off and adsorbed to a copper grid for negative staining    D) 
Mcms treated with mild crosslinking. 1 µL of a 1:20 dilution of fresh glutaraldehyde to 9 µL of a 
1:10 dilution of protein preparation 2733 for 1 minute then quenched with 1 µL of a 1M solution of 
Tris-glycine, the resulting liquid adsorbed to a grid and stained normally. 
 
 
Ultimately, we decided that instead of trying to optimize the protein sample and 
sacrifice yield, it would be faster to focus on high contrast, separated particles and rely on 
diligent pruning and aggressive thresholding during refinements to discard unwanted 
heterogeneity. Among the various conditions tested, 1.5% percent uranyl acetate resulted in 
the best contrast.  Figure 19 shows a representative micrograph.  
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Figure 19 Negative Stain of the Mcm2-7 complex 
1.5% uranyl acetate. Images taken at 40000X magnification, 200kV. The black scale bar represents 
100 nanometers. Inset is 200x200 nanometers 
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4.4 SINGLE PARTICLE RECONSTUCTION WITH EMAN2 
We chose to use the open source EMAN2 software suite for our single particle analysis 
(http://blake.bcm.edu/emanwiki/EMAN2) (Tang et al. 2007). The primary reason was for 
ease of use, as EMAN2’s graphical user interface simplifies 3D refinement by providing 
prompts for building python command strings and arguments. This results in a shallow 
learning curve, which allows a relative novice to run 3D refinements independently. It also 
one of the few processing suites that is entirely self-contained, containing modules for 
boxing particles, CTF tuning, and generating and analyzing 3D models without having to 
switch between programs. 
However, it became clear that particular properties of the Mcm complex (see 
section 4.8) resulted in unique challenges not generally faced in EMAN2 reconstructions. 
Our decision to use convergence on classes and models as a way around the heterogeneity 
problem meant that our data sets needed to be significantly larger than anticipated. This is 
evidenced in Figure 20, which shows the difference in reference class average quality 
between a particle set of 1000, typically enough to generate class averages in EMAN2, and 
a particle set of 40,000 particles 
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 Figure 20: Optimization of reference free class averaging 
A) An initial attempt at generating reference free class averages using a particle count of 1000, 
typically sufficient for generating an initial model in EMAN2, protein preparation 2733 
B) Class averages obtained with a particle set containing 40,000 particles and applying a 0.25 
threshold, protein preparation 2733 
 
 
The large scale of the projects required some deviations from the typical EMAN2 
refinement parameters, which are detailed in Section 2.4.8 
 89 
4.5 THE WILD TYPE MCM 2-7 COMPLEX FORMS AN OPEN RING  
Having prepared a sample grid with recombinant wild type Mcm2-7 hexamers, we 
collected several hundred micrographs, resulting in a total of approximately 45,000 picked 
particles used in the refinement stage. During initial refinement, we found that we had an 
underrepresentation of side views due to the complex’s tendency to land in a limited 
number of orientations. To increase our orientation sampling, we took ~150 images of 
Mcm particles adsorbed to a grid in a high glycerol buffer (see methods for recipe), and 
refined our structure against a smaller set of particles including those from high glycerol 
conditions, before doing further refinement against the entire data set (Figure 21).  
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   C) 
           
Figure 21: 3D reconstruction of S. cerevisiae Mcm2-7 
A) EM map showing views of the Mcm2-7 complex down the central channel and from the side. 
Structure represents 33 thousand particles from protein preparation 2590.  B) Z-slices through the 
3D volume. C) FSC plot, estimated resolution is 26.3 Å 
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We estimate a resolution of 26.3 Å from the Fourier shell correlation (FSC) at the 0.5 
threshold (Figure 21C), which is comparable to previously determined Mcm structures 
from negative stain (see Table 1). These curves are plotted by dividing the data set in two 
and performing two independent refinements, then measuring how well the two 
independent models match. Like the D. melanogaster Mcm2-7, in the absence of 
nucleotide our complex forms an open lockwasher. Notably different is the large size of the 
gap in the complex, the significance of which is discussed further below. 
4.6 THE MCM5BOB1 MUTATION BIASES THE GATE TOWARD A CLOSED 
FORMATION 
We were interested in regulatory mutants that may have phenotypes attributable to aberrant 
gate function. One promising candidate is the bypass of block allele, mcm5bob1 which 
contains a P83L in Mcm5 (Hardy et al. 1997). This mutant previously has been proposed to 
cause a conformational change in Mcm2-7 complex (Fletcher et al. 2003), and secondary 
structure predictions indicate that the mutation may extend the length of a predicted α-helix 
in Mcm5 (Figure 22). 
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 Figure 22: Secondary structure prediction of the mcm5bob1 mutation 
The arrow denotes the break in the α-helix that is removed upon loss of proline 83. Secondary 
structure predicted with PSIPRED (McGuffin et al. 2000) 
 
Given mcm5bob1’s ability to bypass the need for DDK and the secondary structure 
prediction, we hypothesized that this phenotype is due to the mutant’s ability to mimic the 
active (closed) formed of the complex. We tested this by determining the mutant complex’s 
structure (Figure 23 A, B) 
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                       C)  
Figure 23: 3D reconstruction of the Mcm2-7 complex containing mcm5bob1p 
A)  3D volume facing down the central channel of the complex and from the side. Structure was generated 
from 35 thousand particles of protein preparation 2733 B) Z-slices through the projected volume. C) FSC 
plot, estimated resolution of 25 Å. 
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Resolution of the complex containing mcm5bob1 (mcm5bob1 complex) was 
estimated to be 24.8 Å from the Fourier shell correlation at 0.5 (Figure 23C). The complex 
has a noticeably narrower gap than the WT complex. Notably, it also has positive density 
in the middle. This density extending outward is not an artifact, as it can be seen in 
individual particles. The width is consistent with DNA, and we suspect that it is DNA that 
has co-purified with the complex. 
4.7 ATPASE ACTIVE SITE MUTATIONS IN THE 2/5 GATE APPEAR TO 
CONFORM TO BIOCHEMICAL PREDICTIONS 
Given the large discrepancy in the gate size of our WT structure compared to those 
previously published, we wanted to independently verify the state of the gate with ATPase 
active site mutants that have previously been shown to be biased toward an open or closed 
state based on circular ssDNA binding assays. Approximately 25000 particles were picked 
each for complexes containing mutations in the Walker A motif of Mcm5 (5K>A), 
predicted to be open, the Walker B motif of Mcm2 (2DE>NQ), a viable mutant predicted 
to be closed, and the Walker B site of Mcm6 (6DE>NQ). For 2DENQ and 6DENQ, this 
resulted in structures of comparable quality to our WT structure.  
6DENQ, which we expected to look like wild type, does indeed form a large open 
structure (Figure 24A, B). Resolution of this structure was estimated to be 32.6 Å from the 
FSC (Figure 24C). 
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   C) 
                          
Figure 24: 3D reconstruction of mcm6DENQ 
A: 3D volume of the mcm6DENQ open toroid. Structure represents 11 thousand particles from protein 
preparation 2298  B) Z slices through the 3D volume. C) FSC plot, estimated resolution of 32 Å. 
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The mcm2DENQ complex structure, in contrast (Figure 25A, B), looks more like 
the mcm5bob1 structure, however it is not as tightly closed. It is still measurably narrower 
than either the WT or 6DENQ structures. From the FSC curve we estimate a 26.2 Å 
resolution (Figure 25C). 
 Strangely, we were unable to converge on a single solution for the 5KA 
mutant despite quality staining and sufficient particles. A representative refinement is 
shown in Figure 26, which largely appears to noise, however one commonality of all 
mcm5ka refinements is the reduced density in the middle of the 3D volumes, visible in the 
2D slices in 26B. This suggests that mcm5ka is a toroid, but the lack of convergence may 
mean there is no one predominant conformational state. Based on our prior work, we 
expected to see an open ring. Resolution was not estimated, as a convergent solution was 
not reached. 
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        C) 
           
Figure 25: 3D reconstruction of 2DENQ  
A) 3D volume of mcm2DENQ. Structure represents 27 thousand particles from protein preparation 
2251 B) 2D Z-slices through the 3D volume C) FSC plot, estimated resolution 26 of Å. 
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 Figure 26: Mcm5KA does not converge on a toroid 
A) 3D envelope of the refinement. 26 thousand particles from preparation 2512 were used in the 
refinement from B) 2D Z-slices through the 3D model 
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4.8 DISCUSSION 
There were considerable challenges to overcome in this project. Despite the precedence of 
using EMAN2 for single particle reconstruction from negative stain (Tang et al. 2007), we 
faced some unique challenges. Foremost is fact that Mcm2-7 is able to exist in multiple 
conformations. Coupled with the complex’s relatively small size, this hampers the ability 
of the software to align like particles. Further exasperating this problem is the fact that the 
Mcm complex is asymmetric, but is made up of a ring of subunits that are all homologous 
with each other, giving the complex six-fold ‘pseudo-symmetry’  
For these reasons, it became apparent that number of particles required, levels of 
thresholding, and number of iterations of refinements differed significantly from 
complexes more amenable to single particle reconstruction. We solved these issues, to a 
degree, by collecting extensive amounts of data and aggressively culling particles during 
3D refinement. Therefore, we must temper our conclusions with the knowledge that it is 
possible we are converging on a state that does not represent the majority of the particles, 
but merely a state containing a subset of particles conducive to single particle 
reconstruction. However, the agreement between previously published biochemical and 
cell data and our structures lends credence to their validity. 
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 Figure 27: Comparison of WT and the regulatory mutant Mcm2-7 complexes 
A) Wild Type B) mcm5bob1 complex C) mcm2DENQ complex D) mcm6DENQ complex 
The wild type and mcm6denq complexes have large openings at the 2/5 gate, and consequently 
the width of these complexes extends beyond 200 Å.  
 
 
We show evidence that the Mcm2/5 gate has a physiological role in S-phase entry, 
as evidenced by the fact that the regulatory mutant mcm5bob1 makes an Mcm complex that 
is biased toward the closed state. This supports the long standing hypothesis that the DDK 
phosphorylation causes a conformational change in the complex and switches it to a 
biochemically active state (Fletcher et al. 2003). 
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It is unclear why the bob1mutant appears to co-purify with DNA, however there is 
precedence in the literature, as the OCCM complex also co-purifies with DNA (Sun et al. 
2013).  
Comparing the wild type structure with the bob1 mutant, it appears that P83L 
mutation causes Mcm5 to shift inwards toward the gate, close to its position in the CMG 
complex (Costa et al. 2011). Notably, Mcm5 is the subunit to which CDC45 and the GINS 
complex bind, and mcm5bob1 mutants have mis-regulated CDC45 loading at origins of 
replication (Sclafani et al. 2002). The slight opening we see is consistent with the one seen 
in the CMG complex lacking ATP. This provides a model in which the bob1 phenotype 
results in the complex adopting a conformation competent to load CDC45 and GINS 
without the need for DDK phosphorylation (Figure 28). 
 
 
Figure 28: Proposed model for mcm5bob1 bypass 
P83L allows Mcm5 to shift into the space it occupies in the CMG complex, prematurely allowing CDC45 
and GINS to bind. CMG map from (Costa et al. 2011), EMD-1833 coordinates retrieved from EM database  
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 The models of the viable mutants mcm2DENQ and mcm6DENQ are consistent 
with previously reported biochemistry data (Bochman and Schwacha 2008; Bochman and 
Schwacha 2010). Mcm2DENQ behaves as a closed ring in circular DNA binding 
experiments (Bochman and Schwacha 2010), which is recapitulated in our presented 
model. In contrast, Mcm6DENQ behaves like wild type in vitro, and has less severe 
phenotypes than Mcm2DENQ in yeast cell culture (E. Tsai, S. Vijayraghavan, A. 
Schwacha in preparation). In particular, Mcm2DENQ is defective in the DNA replication 
checkpoint control, a phenotype that could be readily accommodated by a closed ring 
conformation. The mcm5KA mutant complex was expected to converge on an open form, 
as predicted from our biochemical data (Bochman and Schwacha 2008), and in our hands 
the asymmetry of an open toroid seems to aid 3D refinement, yet we were unsuccessful at 
converging on a solution. One possibility is that mcm5KA is not ‘locked’ in an open state, 
but instead is adopting a variety of open states which behave similar in bulk biochemical 
assays but are diverse enough to hamper 3D refinement.  
Notably, all the refinements presented here were performed in the absence of ATP, 
as our attempts to refine structures in the presence of ATP were unsuccessful. With 
hypothesize is because total the lack of an opening makes it too difficult for the software to 
distinguish subunits around the ring. 
Altogether these data provide evidence that the Mcm2/5 gate plays an important 
regulatory role in cell cycle progression, and suggest that the physical closing of the ring is 
a critical step for S-phase entry. Furthermore, the fact that at a viable ATPase mutant 
causes a conformational change in the complex indicates that Mcm2-7 uses ATP 
hydrolysis to affect its own conformational state, rather than it being solely dictated by the 
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proteins it is bound to (IE as part of the pre-RC or CMG complex).  In light of previous 
work (Remus et al. 2009; Sun et al. 2013) we think it likely that the difference between 
WT and mcm5bob1 complexes seen here mimics the transition state between the pre-RC 
and the activated CMG complex. 
 
 104 
5.0  DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 THE MCM2-7 COMPLEX IS INHIBITED BY QUINOLONE COMPOUNDS 
The results discussed in Chapter 3 identify Mcm2-7 as a target of the fluoroquinolone 
ciprofloxacin for both in vitro helicase activity and in growth in cell culture. While these 
compounds are not of sufficient potency for therapeutic use, they do provide starting basis 
for future, higher throughput screens. 
5.1.1 Helicase activity is an effective readout for screening Mcm inhibitors 
One concern with any small molecule screen is the choice of assay readout. With any 
screen, a significant number of false positives will be generated by compounds that disrupt 
the assay’s readout. In this regard, helicase activity may be seen disadvantageous when 
compared assays that use ATPase activity as a readout, as the inclusion of DNA provides 
an additional layer of complexity of the assay and provide tested compounds an additional 
substrate to disrupt. However, given that there are multiple AAA+ sites in Mcm2-7 that 
contribute unequally to the complex’s function (Schwacha and Bell 2001) and mutations in 
β-hairpins can uncouple ATPase from helicase activity (Jenkinson and Chong 2006), it 
would appear that ATPase activity is a less sensitive readout, supported by our finding that 
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compounds that disrupt helicase activity with an IC50 below 100 µM have little to no effect 
on bulk ATP hydrolysis (Figure 10A, treatments 1 and 2). 
The effectiveness of measuring helicase activity while counter-screening a related 
helicase is demonstrated by the fact that we identified multiple compounds that appear to 
only inhibit the Mcm complex and not other tested helicases. Furthermore, while we were 
ultimately unsuccessful in identifying an inhibitor that was specific for Mcm2-7 over 
Mcm467, two compounds, ciprofloxacin and 271327, had higher potency against Mcm2-7, 
suggesting that such discrimination is possible and could be attained in a more 
comprehensive, iterative screen. 
5.1.2 The quinolone backbone is an effective scaffold for designing novel Mcm2-7 
inhibitors 
The quinolone scaffold has been used extensively in the development of novel antibiotics, 
and here we demonstrate its utility for use with the eukaryotic replicative helicase. Though 
our screen was small in scale, we nonetheless observed that changes in functional groups 
decorating the quinolone ring modulated selectivity and potency of the helicase inhibitors. 
In particular we observe that substitutions at the C7 position on the quinolone ring 
seem to have the greatest effect on modulating potency, however the small scale of our 
screen means we have not exhaustively tested this possibility. 
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5.1.3 Ciprofloxacin and other compounds are effective in cellular culture 
One surprising result was that the IC50 values for Mcm2-7 helicase activity inhibition and 
∆erg6 growth inhibition by ciprofloxacin were nearly identical. It is unclear if this is 
merely coincidental, but regardless, the fact that even though our compounds are of limited 
potency in vitro they are still able to cause a biological effect at concentrations roughly 
equivalent to stop the enzyme in vitro. While the inhibitors we have described here are not 
nearly potent enough for therapeutic use, they do have sufficient potency for research 
applications, similar to what is used for hydroxyurea (Amberg et al. 2006). 
5.1.4 Possible Mechanisms of fluoroquinolone inhibition 
We were not able to determine a precise mode of action for our inhibitors, however we 
were able to rule out interference with assay substrates and provide some clues as to what 
is being disrupted. The observation that ATPase activity was unaffected by most of our 
compounds was somewhat disappointing at face value, however it did confirm that the 
structural integrity of the Mcm2-7 complexes was unaffected, with the possible exception 
of the compound Mal2-11b. Having ruled out interference with DNA and ATP substrates 
alone (Figures 10c and 10b), three likely scenarios remain.  
The first is that the compounds do disrupt ATP hydrolysis, but only at low turnover 
sites. The fact that increasing ATP concentration can overcome the inhibitory effects of 
some of these compounds does lend credence to this hypothesis, however it’s contradicted 
by the observation that we don’t see the strong selectivity of Mcm2-7 over Mcm467 
suggested by that mechanism. Attempts were made to measure the activity of these low 
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turnover sites in mutant complexes containing Walker A mutations in the 7/3 and 4/7 
active sites, but they had little to no activity above background in the linear range of the 
assay even in the absence of inhibitors. 
The second possibility is that inhibitors disrupt the protein/DNA interface. 
Ciprofloxacin does show a slight defect in ssDNA binding activity, roughly 50% of that 
seen in solvent controls. We attempted to measure the ssDNA binding activity of the 
library compounds, however the chemical properties of the inhibitors interfere with our 
double filter binding assay. The mechanism remains plausible, and the apparent ATP 
rescue we see in Figure 10b may be indicative of the increased ssDNA binding kinetics 
seen in Mcm2-7 upon ATP pre-incubation (Bochman and Schwacha 2007). 
The third possibility is that the inhibitors are allosterically inhibiting DNA 
unwinding. One possibility is that they are uncoupling ATP hydrolysis and helicase 
activity. There is precedence for this in the archaeal literature, as mutations in the helix-2-
insert hairpin abolish helicase activity and actually slightly increase ATPase activity 
(Jenkinson and Chong 2006). Alternatively, coordination between subunits could be lost, 
similar to what is seen when the allosteric control loop (Figure 3) is disrupted (Barry et al. 
2009). 
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5.1.5 Future directions 
Our observation that mcm4chaos3 confers ciprofloxacin resistance was insightful for two 
reasons. First, it provided evidence that the Mcm2-7 is an intracellular target of 
ciprofloxacin. Second, by demonstrating that Mcm mutants exist that are resistant to 
helicase inhibitors, we validated the use of a cell-based assay utilizing the high throughput 
technologies available in yeast. 
 Purifying 6 Mcm proteins (or 11, in the case of CMG) is likely not feasible in the 
quantities needed to screen hundreds of thousands of compounds. Rather than using a 
biochemical assay as the primary screen, recent advances in yeast screening technology 
provide a cheaper and simpler alternative. Given that we have identified one resistant Mcm 
mutant already, it is reasonable to assume that other Mcm mutants to other potential 
inhibitors exist as well. Therefore, one could screen thousands of compounds for their 
ability to arrest growth of drug sensitive yeast strains such as ∆erg6 or ∆pdr5, then counter 
screen with a Mcm mutant library and look for compounds that permit the growth of 
specific Mcm mutants. This can be done efficiently with DNA barcoded mutant libraries, 
which allow for several strains to grow within the same well of a 96 well plate, and qPCR 
can be used to quickly identify and quantify which specific mutants show increased growth 
in the presence of inhibitory compounds (Ho et al. 2009). 
 However, while they might not be feasible as a high throughput assay, helicase 
assays and other biochemical assays will remain a necessary step in validating any 
potential helicase inhibitors. Furthermore, it would also be prudent to test these compounds 
against the CMG complex as well. It has been observed that CDC45 and GINS stimulate 
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the ATPase activity of Mcm2-7(Ilves et al. 2010), so effects we see on helicase activity 
may be decreased or exaggerated in the context of the fully activated form of the complex. 
5.2 PHYSIOLOGICAL RELEVANCE OF THE MCM2/5 GATE 
Chapter 4 describes our efforts to determine the relevance of the Mcm2/5 gate by 
examining the structure of predicted ‘gate mutants.’ 
5.2.1 Differences between the currently determined structures of Mcm2-7 
Our work joins a growing body of structural data available for Mcm2-7, and we observe 
key differences between our structures and those determined previously. The most obvious 
is the large conformational difference seen in our WT structure and those seen by other 
groups (Costa et al. 2011; Lyubimov et al. 2012; Sun et al. 2013)(Figure 29). 
 
Figure 29: Comparison of solved Mcm structures 
A) Drosophila Mcm 2-7 from (Costa et al. 2011) B) S. cerevisiae, this study. C) OCCM complex 
from (Sun et al. 2013) Adapted with the permission of Nature Publishing Group 
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Are these simply species specific differences? Given the high degree of sequence 
conservation of the Mcms among eukaryotes (Bochman and Schwacha 2009), it seems 
unlikely that there are fundamental differences in the way the complex works. However, it 
should be noted that D. melanogaster Mcm2-7 has not yet been shown to possess helicase 
activity outside the context of the CMG complex (Moyer et al. 2006; Ilves et al. 2010).  
One should also remember that the Mcm complex does not exist in a vacuum: 
throughout every stage of the cell cycle it is constant contact with other proteins. It’s 
conceivable that the Mcms of some species are more dependent on those intracellular 
interactions than others. Perhaps D. melanogaster’s Mcm complex does look like the 
complex from yeast, but only when bound to loading factor such as Cdt1. 
Finally, this could be due differences in purification strategies. To date, all 
structures of Mcms containing an “open” structure have been obtained from complexes 
purified from baculovirus ((Costa et al. 2011; Lyubimov et al. 2012) and this study). Since 
the phosphorylation state of baculovirus produced proteins is unknown, and given the 
importance phosphorylation plays in activating the complex, it possible differences in the 
phosphorylation state of these complex are responsible for the observed structural 
differences.  
5.2.2 Phenotype of the mcm5bob1 mutation 
For several years the Sclafani lab has championed the cause of the bypass of block mutant, 
bob1, which bypasses the need for the essential regulatory kinase DDK.  Modeling based 
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on the crystal structure of the N-terminal fragment of the M. thermautotrophicus Mcm 
suggested a “domain push” model as the mechanism for the mutant’s ability to dispense 
with DDK by allowing stochastic binding of CDC45 (Fletcher et al. 2003; Hoang et al. 
2007) 
Analysis of the structure of the Mcm5bob1 complex supports this hypothesis. 
Contrasting it with the wild type structure, it appears that the P83L causes Mcm5 to tuck 
into the position it occupies as a member of the CMG complex. This suggests that the 
primary consequence of CDC7/DBF4 (DDK) phosphorylation results in a conformational 
change in the Mcm complex, allowing GINS and CDC45 to bind. This also explains why 
we and other groups have failed to make an equivalent mutation in Mcm2 that mimics the 
bob1 phenotype, as Mcm2 does not mediate contacts between GINS, CDC45, and the rest 
of the complex as Mcm5 does. 
5.2.3 ATPase active site mutants and their relationship to the gate  
The observation that mcm2DENQ is also preferentially closed lends credence to the model 
that the 6/2 active site is regulating the 2/5 gate (Bochman and Schwacha 2010). However, 
given that the structure was determined in the absence of ATP, why is an ATPase active 
site mutant causing this effect on the complex’s conformation?  
We have long posited that 2DENQ plays a regulatory role (see Figure 1). Given 
that the 6/2 active site has extremely low turnover (Schwacha and Bell 2001), it would 
seem that the active site’s function doesn’t depend on several rounds of ATP binding and 
hydrolysis like those required for helicase activity, but instead uses ATP as a molecular 
switch. Although canonically Walker B motifs are associated with the coordination of 
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magnesium and water during ATP hydrolysis, there is evidence to suggest that in the Mcm 
complex mutations in this motif may also have an effect on ATP binding (Gomez et al. 
2002). Therefore it’s possible that the difference we are observing is due to a lack of ATP 
or ADP that normally co-purifies in that subunit in wild type complexes. 
Another possibility is that the ATPase activity at the 6/2 site is required to transmit 
the state of the 2/5 gate to neighboring subunits. Our wild type Mcm2-7 structure has a ring 
opening large enough that subunits besides Mcm2 and Mcm5 likely have a role in its 
opening. Mcm2DENQ still has a small opening, but if it is deficient in communicating the 
state of the 2/5 active site to Mcm6, this may explain why the opening is much smaller than 
the wild type complex. It’s conceivable that the other proteins involved in the G1 to S-
phase condition are sufficient to compensate for this defect, which is why mcm2DENQ 
mutations in yeast are viable (Schwacha and Bell 2001). Unlike mcm5bob1 mutants 
(Hoang et al. 2007), mcm2DENQ does not have origins which prematurely fire even 
though both mutants are predisposed to a closed position. It does, however, have late origin 
firing defects, as well as defects in the DNA replication checkpoint and sister chromatid 
cohesion defects. These regulatory defects may be symptomatic of a lack of 
communication between regulatory elements and structural states in Mcm2-7 normally 
communicated by the Mcm 6/2 active sites. 
5.2.4 Future directions 
Several questions arise now that now that we have identified a mutation that disrupts the 
Mcm gate. How does mcm5bob1 get loaded onto DNA? Does it bind origin DNA more 
tightly than WT? It would be desirable to collect data on the mutation as part of the 
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different higher order complexes the Mcm complex becomes part of as it progresses 
through the cell cycle. Mcm5bob1 in conjunction with Cdt1/Cdc6, are part of the OCCM 
complex, the pre-RC, or the CMG complex would shed light on many of these questions.  
We also have evidence that at least one Mcm active site mutation causes a 
conformational change in the ring. Curiously, mutations in the Walker A and arginine 
finger motifs in the 6/2 active site are lethal (Schwacha and Bell 2001; Bochman et al. 
2008). Why is this the case? Do these mutations cause a conformational change greater in 
severity? Structure determination of these mutants may give us answers we cannot achieve 
genetically. 
Alternatively, we could take advantage of the variety of synthetic DNA substrates 
available. A complex that is preferentially closed may interact differently with DNA than 
one that is open, perhaps by binding tighter, or lacking an ability to bind DNA origin-like 
bubbles.  
Finally, labelled subunits with MBP fusions would allow us to make definitive 
subunit assignments. The presence of an open gate narrows down the possibilities to two 
orientations, but in a fully closed complex that landmark is lost. These tags may also 
provide enough asymmetry to aid in 3D refinements of closed complexes, which have been 
unsuccessful in our hands. 
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APPENDIX A 
APPENDIX: INHIBITION OF MCM2-7, MCM467, AND SV40 LARGE T 
ANTIGEN BY LIBRARY COMPOUNDS 
The following compounds were added to helicase reactions at a final concentration of 
1mM. Numbers indicate percent DNA unwinding relative to solvent control and represent 
≥2 repetitions. 
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